Cyclohexyl derivative dual NOP / mop agonist

By designing novel cycloalkyl derivatives that target MOP and NOP receptors, the side effects of existing μ-opioid receptor agonists have been resolved, resulting in a highly effective analgesic with low side effects, suitable for the treatment of various types of pain.

WO2026233197A1PCT designated stage Publication Date: 2026-11-12NANJING DEHENG BIOPHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/093835
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-12-18
Filing Date
2026-04-29
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing μ-opioid receptor (MOP) agonists are prone to inducing central side effects such as respiratory depression, constipation, sedation, increased tolerance, and addiction with long-term use, and their efficacy in chronic pain and neuropathic pain is limited. There is a need to develop novel MOP/NOP dual agonists that have both high analgesic efficacy and low side effects.

Method used

A class of novel cycloalkyl derivatives was designed to target the dual agonist mechanisms of MOP and NOP, exhibiting excellent agonist activity, physicochemical properties, cardiac safety, and analgesic efficacy. Highly efficient synergistic activation of MOP and NOP receptors can be achieved by preparing compounds of formula I and their isomers, racemates, prodrugs, deuterated compounds, or pharmaceutically acceptable salts thereof.

Benefits of technology

It achieves significant analgesic effects, reduces euphoria, respiratory depression and the risk of addiction, improves water solubility and oral bioavailability, ensures good metabolic stability and cardiovascular safety, and is suitable for a variety of pain types, including chronic neuropathic pain.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026093835_12112026_PF_FP_ABST
    Figure CN2026093835_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a cyclohexyl derivative, and a preparation method therefor and a use thereof, the cyclohexyl derivative acting as a dual NOP / MOP agonist and being a compound as represented by formula I, an isomer, a racemate, a prodrug, a deuterated compound or a pharmaceutically acceptable salt thereof, wherein the definitions of each group and substituent are as described in the description.
Need to check novelty before this filing date? Find Prior Art

Description

A class of cyclohexyl derivative dual agonists of NOP and MOP

[0001] This application claims priority to Chinese Patent Application No. 202510584563.8, filed on May 7, 2025, entitled "A Dual Agonist of Cyclohexyl Derivatives NOP and MOP", filed on May 29, 2025, entitled "A Dual Agonist of Cyclohexyl Derivatives NOP and MOP", and filed on December 18, 2025, entitled "A Dual Agonist of Cyclohexyl Derivatives NOP and MOP", the entire contents of which are incorporated herein by reference. Technical Field

[0002] This invention relates to the field of medicinal chemistry, specifically to a class of cyclohexyl derivatives as dual agonists of NOP and MOP, their preparation methods, pharmaceutical compositions, and their use in the preparation of drugs for treating diseases such as pain. Background Technology

[0003] Pain, as a core clinical symptom of many acute and chronic diseases, has complex mechanisms of occurrence and maintenance, involving extensive neural networks, neurotransmitter systems, and multiple intracellular signaling pathways, exhibiting high heterogeneity and dynamism. As the most common chief complaint in clinical practice, pain severely impairs patients' quality of life and daily functioning, becoming an important target for treatment intervention. However, in cases of cancer pain, postoperative pain, and chronic neuropathic pain, there remains a significant unmet clinical need for analgesics with proven efficacy and manageable side effects.

[0004] Currently, opioids, represented by μ-opioid receptor (MOP) agonists (such as morphine, oxycodone, and fentanyl), remain the first-line drugs for controlling moderate to severe pain and are widely used in acute and postoperative pain management. However, traditional MOP agonists are prone to inducing serious central nervous system side effects such as respiratory depression, constipation, sedation, increased tolerance, and addiction during long-term use, significantly limiting their application in chronic and neuropathic pain. Furthermore, some MOP agonists have limited efficacy in certain treatment-resistant pain models, further highlighting the urgent need to develop novel analgesic strategies.

[0005] Opioid receptors are a class of G protein-coupled receptors (GPCRs), including three classic subtypes: μ (MOP), κ (KOP), and δ (DOP) receptors, as well as the nociceptin opioid peptide receptor (NOP receptor, formerly known as opioid receptor-like 1, ORL-1), which has high structural homology with the opioid receptor family. These receptors are widely distributed in tissues such as the brain, spinal cord, sensory nerve endings, and gastrointestinal tract, playing important physiological functions in pain transmission, mood regulation, reward mechanisms, and stress responses. Unlike MOP receptors, NOP receptors exhibit unique pharmacological properties in analgesia and addiction regulation. Studies have shown that NOP receptor agonists can produce significant antinociceptive effects in various animal models, especially in chronic inflammatory and neuropathic pain models, without being accompanied by significant euphoria, respiratory depression, or dependence (Schroeder et al., Br J Pharmacol, 2014). Furthermore, the upregulation of NOP receptor expression in chronic pain states further suggests its potential advantages in long-term pain management. It is worth noting that NOP receptor agonists have also shown therapeutic potential in interventions for mood disorders and substance use disorders (Witkin et al., Pharmacol Ther, 2014; Jenck et al., PNAS, 1997).

[0006] To achieve a balance between analgesic efficacy and safety, recent research has focused on developing dual agonists that simultaneously activate both MOP and NOP receptors. These compounds aim to integrate the potent analgesic effect of MOP receptors with the regulatory advantages of NOP receptors on side effects such as addiction and respiratory depression, thereby achieving a higher therapeutic index and a lower risk of abuse. Non-human primate studies have shown that MOP / NOP dual agonists can achieve analgesic effects comparable to traditional MOP agonists, while significantly reducing euphoria, respiratory depression, and self-administration behavior, demonstrating lower addiction potential (Khroyan et al., J Pharmacol Exp Ther, 2009; Toll et al., Trends Pharmacol Sci, 2016).

[0007] Representative drug candidates include Cebranopadol, an orally active MOP / NOP dual agonist that has demonstrated excellent analgesic efficacy, good tolerability, and low abuse potential in animal models of chronic pain (Linz et al., Pain, 2014); and AT-121, which has shown potent analgesic effects in non-human primate models, without euphoria or respiratory depression side effects, and without self-administration behavior, with a significantly reduced risk of addiction (Ding et al., PNAS, 2018). Furthermore, spirocyclohexane compounds, due to their unique three-dimensional structural framework, can achieve high affinity and selective binding to MOP and NOP receptors, and possess good oral bioavailability and metabolic stability, making them an important direction for optimizing MOP / NOP dual agonists. However, while published spiro[cyclohexane-pyridinoindole] compounds (e.g., WO2012 / 013343) have shown good efficacy, they still suffer from poor water solubility, low bioavailability, potential hERG channel toxicity, and a narrow safety window, limiting their further drug development and clinical translation.

[0008] Therefore, developing novel MOP / NOP dual agonists with the following advantages has become a key issue that urgently needs to be addressed: highly efficient synergistic activation of MOP and NOP receptors to achieve excellent analgesic effects; improved drug safety, significantly reducing euphoria, respiratory depression, and the risk of addiction; improved water solubility and oral bioavailability; ensuring good metabolic stability and cardiovascular safety; and applicability to various types of pain, including chronic neuropathic pain. Summary of the Invention

[0009] Based on the above-mentioned research status and clinical needs, this invention proposes a novel cycloalkyl derivative that targets the dual agonist mechanisms of MOP and NOP, exhibiting excellent agonist activity, physicochemical properties, cardiac safety, and analgesic efficacy, providing a safer, more effective, and sustainable treatment option for analgesic drug development.

[0010] This invention provides a compound of formula I:

[0011] Its isomers, racemates, prodrugs, deuterated compounds, or pharmaceutically acceptable salts thereof, wherein:

[0012] Ring B is a nitrogen-containing 5-7 membered heterocyclic alkyl group, containing... 5-6 membered heterocyclic alkyl groups, nitrogen-containing 5-6 membered heteroaryl groups;

[0013] The ring C is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl;

[0014] m, n, and p are integers from 1 to 4;

[0015] Each R1, each R2, each R3, R 1a3 R 1d Each of the following can be independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', -COOR5, -COR5, -NR5S(=O)2R6, -SR5, -OR5, =O, -S(=O)2R5, S(=O)2NR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, cyano, -C 0-6 -NR5R5'、-C 0- 6-CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 0-6 -SR5, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -C 0-6 -COR5、-C 0-6 -C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 Substitution of cycloalkoxy, 6-10 aryl, 5-10 heteroaryl, -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5' substituents;

[0016] In one embodiment of the invention, each R1, each R2, each R3, R 1a3 R 1d Each of the following is independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10-membered heterocycloalkyl, C3-8 cycloalkoxy, 3-10-membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further being selected by one or more independently from hydrogen, halogen, hydroxyl, cyano, -C 0-6 -NR5R5'、-C0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1- 6-alkoxy, -C 0-6 -COR5、-C 0-6 -C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 Substitution of cycloalkoxy, 6-10 aryl, 5-10 heteroaryl, -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5' substituents;

[0017] In one embodiment of the invention, each R1, each R2, each R3, R 1a3 R 1d Each of the following is independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substitution of alkoxy groups;

[0018] R 1a1 R 1a2 Each independently is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy; alkyl, alkoxy may be further selected by one or more independently from hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Substitution of alkoxy groups;

[0019] R5, R5', and R6 are independently selected from H, amino, and C, respectively. 1-6 Alkyl, C 3-8 Cycloalkyl, 3-10 heterocycloalkyl, 6-10 aryl, 5-10 heteroaryl, -C0-6 -OR7; where R7 is C 1-6 alkyl;

[0020] In one embodiment of the present invention, R5, R5', and R6 are each independently selected from H and C. 1-6 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl;

[0021] Or R5, R5', together with the atoms they are connected to, form C. 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, the C 3- 8-membered cycloalkyl, 3-10-membered heterocyclic alkyl, optionally further selected by one or more groups selected from hydroxyl, amino, halogen, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-8 Substitution with cycloalkyl, 3-10 membered heterocyclic alkyl, and =O substituents.

[0022] In one embodiment of the present invention, R5 and R5' are independently selected from H and C, respectively. 1-6 Alkyl, C 3-8 Cycloalkyl, 3-10 heterocycloalkyl, 6-10 aryl, 5-10 heteroaryl.

[0023] In one embodiment of the present invention, ring B is

[0024] In one embodiment of the present invention, ring B is...

[0025] In one embodiment of the present invention, ring B is... Indicates ring B Bit N and Connected.

[0026] In one embodiment of the present invention, ring B is... Indicates ring B Bit N and Connected.

[0027] In one embodiment of the invention, the compound of formula I, its isomer, racemate, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof has the following compound structure:

[0028] The ring C is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl;

[0029] m and p are integers from 1 to 4;

[0030] X is selected from CR 2b R 2b '、C=O;

[0031] Y is selected from CR 2b R 2b '、C=O;

[0032] Z is selected from CR 2d R 2d '、O、S、NR 2d ;

[0033] U is selected from N, CR 2b ;

[0034] V is selected from N and CR. 2c ;

[0035] Each R1, each R3, R 1a3 R 1d R 2b R 2b '、R 2c R 2c '、R 2d R 2d '、R 2e R 2e '、R 2f R 2f Each of the following is independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', -COOR5, -COR5, -NR5S(=O)2R6, -SR5, -OR5, =O, -S(=O)2R5, S(=O)2NR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, cyano, -C 0-6-NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1- 6-alkyl, C 0-6 -SR5, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -C 0-6 -COR5、-C 0-6 -C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 Substitution of cycloalkoxy, 6-10 aryl, 5-10 heteroaryl, -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5' substituents;

[0036] In one embodiment of the present invention, each R3, R 1a3 R 1d R 2b R 2b '、R 2c R 2c '、R 2d R 2d '、R 2e R 2e '、R 2f R 2f Each of the following is independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, cyano, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -C 0-6 -COR5、-C 0-6 -C 3-8Cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 Substitution of cycloalkoxy, 6-10 aryl, 5-10 heteroaryl, -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5' substituents;

[0037] In one embodiment of the present invention, each R3, R 1a3 R 1d R 2b R 2b '、R 2c R 2c '、R 2d R 2d '、R 2e R 2e '、R 2f R 2f Each is independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substitution of alkoxy groups;

[0038] t is selected from 0, 1, or 2;

[0039] s is selected from 0 or 1;

[0040] R 1a1 R 1a2 Each independently is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy; alkyl, alkoxy may be further selected by one or more independently from hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Substitution of alkoxy groups;

[0041] R5, R5', and R6 are independently selected from H, amino, and C, respectively. 1-6 Alkyl, C3-8 Cycloalkyl, 3-10 heterocycloalkyl, 6-10 aryl, 5-10 heteroaryl, -C 0-6 -OR7; where R7 is C 1-6 alkyl;

[0042] In one embodiment of the present invention, R5, R5', and R6 are each independently selected from H and C. 1-6 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl;

[0043] Or R5, R5 together with the atoms connected to them, forms C. 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, the C 3- 8-membered cycloalkyl, 3-10-membered heterocyclic alkyl, optionally further selected by one or more groups selected from hydroxyl, amino, halogen, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-8 Substitution with cycloalkyl, 3-10 membered heterocyclic alkyl, and =O substituents.

[0044] In one embodiment of the invention, the compound of formula I, its isomer, racemate, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof has the following compound structure: IIIa1-IIIa2, IIIb1, IIIc1-IIIc3, IIId1, IIIe1, IIIf1, IIIg1, IIIh1, IIIi1, IIIj1, IIIk1.

[0045] m is an integer from 1 to 4;

[0046] X is selected from CR 2b R 2b '、C=O;

[0047] Y is selected from CR 2b R 2b '、C=O;

[0048] Z is selected from CR 2d R 2d '、O、S、NR 2d ;

[0049] U is selected from N, CR 2b ;

[0050] V is selected from N and CR. 2c ;

[0051] Each R1, R 1a3 R 1d R 2b R 2b '、R 2c R 2c '、R 2d R 2d '、R 2e R 2e '、R 2f R 2f '、R 3c R 3d R 3e R 3f Each of the following can be independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', -COOR5, -COR5, -NR5S(=O)2R6, -SR5, -OR5, =O, -S(=O)2R5, S(=O)2NR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, cyano, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 0-6 -SR5, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -C 0-6 -COR5、-C 0-6 -C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 Substitution of cycloalkoxy, 6-10 aryl, 5-10 heteroaryl, -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5' substituents;

[0052] In one embodiment of the present invention, each R1, R 1a3 R 1d R 2b R 2b '、R 2c R 2c '、R2d R 2d '、R 2e R 2e '、R 2f R 2f '、R 3c R 3d R 3e R 3f Each of the following is independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, cyano, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -C 0-6 -COR5、-C 0-6 -C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 Substitution of cycloalkoxy, 6-10 aryl, 5-10 heteroaryl, -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5' substituents;

[0053] In one embodiment of the present invention, each R1, R 1a3 R 1d R 2b R 2b '、R 2c R 2c '、R 2d R 2d '、R 2e R 2e '、R 2f R 2f '、R 3c R 3d R 3e R 3fEach of the following is independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substitution of alkoxy groups;

[0054] t is selected from 0, 1, or 2;

[0055] s is selected from 0 or 1;

[0056] Preferably, R 1a3 Selected from

[0057] Each R4 is selected from hydrogen, halogen, hydroxyl, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy;

[0058] q is an integer between 1 and 5;

[0059] R 1a1 R 1a2 Each independently is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy; alkyl, alkoxy may be further selected by one or more independently from hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Substitution of alkoxy groups;

[0060] R5, R5', and R6 are independently selected from H, amino, and C, respectively. 1-6 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl;

[0061] In one embodiment of the present invention, R5, R5 ’ R6 and R6 are independently selected from H and C, respectively. 1-6 Alkyl, C 3-8 Cycloalkyl, 3-10 heterocycloalkyl, 6-10 aryl, 5-10 heteroaryl, -C 0-6 -OR7; where R7 is C 1-6 alkyl;

[0062] Or R5, R5', together with the atoms they are connected to, form C. 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, the C 3- 8-membered cycloalkyl, 3-10-membered heterocyclic alkyl, optionally further selected by one or more groups selected from hydroxyl, amino, halogen, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 3-8 Substitution with cycloalkyl, 3-10 membered heterocyclic alkyl, and =O substituents.

[0063] In one embodiment of the invention, the compound, isomer, racemate, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof of formula I has the following compound structure:

[0064] The ring C is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl;

[0065] m and p are integers from 1 to 4;

[0066] X is selected from CR 2b R 2b '、C=O;

[0067] U is selected from N, CR 2b ;

[0068] V is selected from N and CR. 2c ;

[0069] Each R1, each R3, R 1a3 R 1d R 2b R 2b '、R 2c R 2e R 2e '、R 2f R 2fEach is independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substitution of alkoxy groups;

[0070] R 1a1 R 1a2 Each independently is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy; alkyl, alkoxy may be further selected by one or more independently from hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Substitution of alkoxy groups;

[0071] R5 and R5' are independently selected from H and C, respectively. 1-6 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl;

[0072] t is selected from 0, 1 or 2.

[0073] In one embodiment of the invention, the compound, isomer, racemate, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof of formula I has the following compound structure: IIIa1-IIIa2, IIIb1, IIIc1-IIIc3, IIId1, IIIe1.

[0074] m is an integer from 1 to 4;

[0075] X is selected from CR 2b R 2b '、C=O;

[0076] U is selected from N, CR 2b ;

[0077] V is selected from N and CR. 2c ;

[0078] Each R1, each R3, R 1a3 R 1d R 2b R 2b '、R 2c R 2e R 2e '、R 2f R 2f '、R 2c '、R 2d R 2d '、R 3c R 3d R 3e R 3f Each of the following is independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', 6-10 aryl, 5-10 heteroaryl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 3-8 Cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy further selected by one or more independently selected from hydrogen, halogen, hydroxyl, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substitution of alkoxy groups;

[0079] R 1a1 R 1a2 Each independently is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy; alkyl, alkoxy may be further selected by one or more independently from hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Substitution of alkoxy groups;

[0080] R5 and R5' are independently selected from H and C, respectively. 1-6 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl;

[0081] t is selected from 0, 1, or 2;

[0082] Preferably, R 1a3 Selected from

[0083] Each R4 is selected from hydrogen, halogen, hydroxyl, -C 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy;

[0084] q is an integer between 1 and 5;

[0085] Y is selected from CR 2b R 2b '、C=O;

[0086] Z is selected from CR 2d R 2d '、O、S、NR 2d ;

[0087] s is selected from 0 or 1.

[0088] The compound, isomer, racemate, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof described in any of the preceding claims, preferably, Selected from

[0089] Preferably, X and Y are each independently C=O and -CH2-;

[0090] Preferably, Z is selected from O, -CH2-, -NH-, and -N(CH3)-;

[0091] Preferably, R 1d Selected from H and hydroxyl groups;

[0092] Preferably, U and V are each independently N and CH;

[0093] Preferably, the ring C is phenyl, pyridinyl, thiophene, pyrazinyl, pyrimidinyl, pyridazinyl, pyrroleyl, pyrazolyl, imidazoleyl, or thiazolyl.

[0094] Preferably, R 1a3 Selected from C 1-6 Alkyl, phenyl, pyridyl, thiophene, wherein the alkyl, phenyl, pyridyl, or thiophene group is further composed of one or more radicals selected from hydrogen, halogen, hydroxyl, cyano, or -C. 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C1-6 Alkoxy, -C 0-6 -COR5、-C 0-6 -C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 Substitution of cycloalkoxy, 6-10 aryl, 5-10 heteroaryl, -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5'.

[0095] Preferably, R 1a3 Selected from C 1-6 Alkyl, phenyl, pyridyl, thiophene, wherein the alkyl, phenyl, pyridyl, or thiophene group is further influenced by one or more elements selected from hydrogen, halogen, hydroxyl, or -C. 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Substitution of alkoxy groups.

[0096] A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

[0097] On the other hand, the present invention also relates to a pharmaceutical composition comprising any of the compounds, isomers, racemates, prodrugs, deuterated compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients.

[0098] On the other hand, the present invention also relates to the use of any of the compounds, isomers, racemates, prodrugs, deuterated compounds or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof in the preparation of medicaments for the treatment and / or prevention of diseases or disorders mediated by dual agonists of NOP and MOP.

[0099] On the other hand, the present invention also relates to the use of any of the compounds, isomers, racemates, prodrugs, deuterated compounds or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof in the preparation of medicaments for treating and / or preventing neurological disorders; preferably, the neurological disorders include, but are not limited to, pain, neurodegenerative diseases, neuroinflammatory diseases, neuropsychiatric disorders, and drug abuse / dependence.

[0100] On the other hand, the present invention also relates to the use of any of the compounds, isomers, racemates, prodrugs, deuterated compounds or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof in the preparation of medicaments for the treatment and / or prevention of anxiety states, stress and stress-related syndromes, depression, epilepsy, Alzheimer's disease, senile dementia, general cognitive impairment, learning and memory impairment (as nootropics), withdrawal symptoms, alcohol and / or drug and / or drug abuse and / or dependence, sexual dysfunction, cardiovascular disease, hypotension, hypertension, tinnitus, pruritus, migraine, hearing loss, intestinal motility deficiency, impaired food intake, anorexia, obesity, movement disorders, diarrhea, cachexia, urinary incontinence, or as muscle relaxants, anticonvulsants or anesthetics, or for administration in combination with opioid analgesics or anesthetics in treatment, for diuresis or inhibition of natriuretic excretion, for anxiolytics, for regulating motor activity, for regulating neurotransmitter secretion and treating associated neurodegenerative diseases, for treating withdrawal symptoms and / or for reducing opioid addiction. Detailed Implementation

[0101] Through extensive and in-depth research, the inventors of this application have developed for the first time a dual agonist of NOP and MOP with the structure of Formula I.

[0102] Detailed explanation: Unless otherwise stated or specifically stated, the terms used in the specification and claims shall have the following meanings.

[0103] “C 1-6 "Alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group containing 1 to 6 carbon atoms, preferably C16. 1-4 Alkyl, C 1-4 Alkyl groups refer to straight-chain alkyl groups comprising 1 to 4 carbon atoms and branched alkyl groups, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, or their various branched isomers. "C 1-4 "Alkyl" refers to straight-chain alkyl groups containing 1 to 4 carbon atoms and branched alkyl groups.

[0104] “C 0-6 "Refers to "C" 0-6 "Alkylene" refers to straight-chain alkylenes containing 0 to 6 carbon atoms and branched alkylenes.

[0105] “C3-8 "Cycloalkyl" refers to a substituent in a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon. A partially unsaturated cyclic hydrocarbon is one that may contain one or more (preferably 1, 2, or 3) double bonds, but none of the rings has a fully conjugated π-electron system. Cycloalkyl groups are classified as monocyclic or polycyclic, and preferably include 3 to 6 carbon atoms.

[0106] Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptanetrienyl, and cyclooctyl.

[0107] Polycyclic cycloalkyl groups include spirocyclic, fused-ring, and bridged-ring cycloalkyl groups. "Spirocycloalkyl" refers to a polycyclic group in which a single carbon atom (called a spiro atom) is shared between the rings. These groups may contain one or more (preferably 1, 2, or 3) double bonds, but none of the rings has a fully conjugated π-electron system. Based on the number of shared spiro atoms between the rings, spirocycloalkyl groups are classified into monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl groups. Spirocycloalkyl groups include, but are not limited to:

[0108] "Fused cyclic alkyl" refers to a polycyclic aromatic hydrocarbon group in which each ring shares an adjacent pair of carbon atoms with the other rings in the system. One or more rings may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a fully conjugated π-electron system. Based on the number of constituent rings, fused cyclic alkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused cyclic alkyl groups include, but are not limited to:

[0109] "Bridged cycloalkyl" refers to a polycyclic aromatic hydrocarbon group in which any two rings share two non-directly bonded carbon atoms. These groups may contain one or more (preferably 1, 2, or 3) double bonds, but none of the rings has a fully conjugated π-electron system. Based on the number of constituent rings, bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged cycloalkyl groups include, but are not limited to:

[0110] "3-10 membered heterocyclic alkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent. The partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2, or 3) double bonds, but none of the rings has a fully conjugated π-electron system. In the heterocyclic group, one or more (preferably 1, 2, 3, or 4) ring atoms are selected from nitrogen, oxygen, C=O, or S(O)r (where r is an integer 0, 1, or 2), but excluding the -OO-, -OS-, or -SS- ring portions. The remaining ring atoms are carbon. Heterocyclic groups comprising 3 to 8 ring atoms are preferred. Heterocyclic groups comprising 3 to 6 ring atoms are more preferred.

[0111] Monocyclic heterocyclic groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, oxobutyl, and tetrahydrofuranyl. wait.

[0112] Polycyclic heterocyclic groups include spirocyclic, fused-ring, and bridged-ring heterocyclic groups. A "spiroheterocyclic group" refers to a polycyclic heterocyclic group in which one or more (preferably 1, 2, 3, or 4) ring atoms are selected from nitrogen, oxygen, C=O, or S(O)r (where r is an integer 0, 1, or 2), and the remaining ring atoms are carbon. These may contain one or more double bonds (preferably 1, 2, or 3), but none of the rings has a fully conjugated π-electron system. Spiroheterocyclic groups are classified into monospirocyclic, bispirocyclic, or polyspirocyclic groups based on the number of shared spiro atoms between the rings. Spiroheterocyclic groups include, but are not limited to:

[0113] "Fused heterocyclic group" refers to a polycyclic heterocyclic group in which each ring in the system shares a pair of adjacent atoms with other rings in the system. One or more (preferably 1, 2, 3, or 4) rings may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a fully conjugated π-electron system. The one or more (preferably 1, 2, 3, or 4) ring atoms are selected from nitrogen, oxygen, C=O, or S(O)r (where r is an integer 0, 1, or 2), and the remaining ring atoms are carbon. Based on the number of constituent rings, they can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic alkyl groups. Fused heterocyclic groups include, but are not limited to:

[0114] "Bridged heterocyclic groups" refer to polycyclic heterocyclic groups in which any two rings share two non-directly bonded atoms. These groups may contain one or more (preferably 1, 2, or 3) double bonds, but none of the rings has a fully conjugated π-electron system. One or more (preferably 1, 2, 3, or 4) ring atoms are selected from nitrogen, oxygen, C=O, or S(O)r (where r is an integer 0, 1, or 2), and the remaining ring atoms are carbon. Based on the number of rings, they can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic groups. Bridged heterocyclic groups include, but are not limited to:

[0115] "6-10 aryl" refers to all-carbon aryl groups containing 6-10 carbons, including but not limited to: phenyl and naphthyl.

[0116] "5-10 heteroaryl" refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms, including nitrogen, oxygen, C=O and S(O)r (where r is an integer 0, 1, 2), preferably containing 5, 6, 7, 8, 9 or 10 ring atoms, including but not limited to furanyl, thiophene, pyrrole, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, pyridinyl, pyridinyl, pyrazinyl or triazinyl, etc.

[0117] “C 1-6 "Alkoxy" refers to -OC 1-6 Alkyl, wherein the definition of alkyl is as described above, for example "C 1-4 "Alkoxy" refers to alkyloxy groups containing 1-4 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, butoxy, etc.

[0118] “C 3-8 "Cycloalkoxy" refers to -OC 3-8 cycloalkyl, wherein C 3-8 The definition of cycloalkyl is as described above, for example, "C 3-8 "Cycloalkoxy" refers to a cycloalkyloxy group containing 3-8 carbons, "C 3-6 "Cycloalkoxy" refers to cycloalkyloxy groups containing 3-6 carbons, including but not limited to cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, etc.

[0119] Halogenated C 1-6 "Alkyl" refers to 1-6 carbon alkyl groups on an alkyl group in which the hydrogen atoms are optionally replaced by fluorine, chlorine, bromine, or iodine atoms, including but not limited to difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, etc.

[0120] "Halogen" refers to fluorine, chlorine, bromine, or iodine.

[0121] "Independently" means "optional" or "optionally" to replace, meaning that the event or situation described below may but does not have to occur. This description includes the situation where the event or situation occurs or does not occur, that is, it includes both substituted and unsubstituted scenarios.

[0122] "Substitution" refers to the independent replacement of one or more "hydrogen atoms" in a group by a corresponding number of substituents. It goes without saying that substituents are only in their possible chemical positions, conforming to the valence bond theory in chemistry, and those skilled in the art can determine (through experiment or theory) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated bond (such as an alkene).

[0123] In this invention, Used to describe chemical bonds, which are points where a portion or a substituent is connected to a core or skeletal structure.

[0124] "0-6" refers to 0, 1, 2, 3, 4, 5 or 6.

[0125] "1-6" refers to 1, 2, 3, 4, 5 or 6.

[0126] "Integers from 1 to 4" refers to 1, 2, 3, and 4.

[0127] "Integers from 1 to 5" refers to 1, 2, 3, 4, and 5.

[0128] "Isomers" are stereoisomers, which are isomers resulting from different spatial arrangements of atoms in a molecule. They can be divided into two main categories: cis-trans isomers and enantiomers, or enantiomers and diastereomers. Stereoisomers caused by the rotation of single bonds are called conformational stereoisomers, sometimes also called rotamers. Stereoisomers caused by bond length, bond angle, the presence of double bonds, or rings within the molecule are called configuration stereoisomers. Configuration stereoisomers are further divided into two categories. Isomers caused by the inability of single bonds in double bonds or cyclic carbon atoms to rotate freely are called geometric isomers, also known as cis-trans isomers, and they have two configurations: Z and E. For example, cis-2-butene and trans-2-butene are a pair of geometric isomers. Stereoisomers with different optical properties due to the lack of antiaxial symmetry in their molecules are called optical isomers, which are classified into R and S configurations. In this invention, unless otherwise specified, "stereoisomer" can be understood to include one or more of the enantiomers, configuration isomers, and conformational isomers described above.

[0129] In a preferred embodiment, the cis or trans isomer thus named has an excess of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%.

[0130] Any asymmetric atom (e.g., carbon, etc.) in the compounds of the present invention may exist in racemic or enantiomerically enriched forms, such as (R)-, (S)-, (R,R)-, (R,S)-, (S,R)-, and (S,S)- configurations. In some embodiments, each asymmetric atom has at least 0% enantiomeric excess, at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess with respect to the (R)- or (S)- configuration. The independent synthesis of enantiomers and diastereomers, or their chromatographic separation, may be achieved by suitable modifications of the methods disclosed herein, as known in the art. Their absolute stereochemistry can be determined by X-ray crystallography of the crystallized products or intermediates, and, if necessary, by derivatization with reagents containing asymmetric centers of known absolute configuration or sufficiently heavy atoms to achieve absolute partitioning.

[0131] Methods suitable for separating enantiomers and diastereomers are known to those skilled in the art. Examples include column chromatography, preparative HPLC, and crystallization. In principle, targeted synthesis methods, in which an excess of one isomer is formed, are also known to those skilled in the art.

[0132] In this invention, "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable acid addition salt, including inorganic acid salts and organic acid salts, which can be prepared by methods known in the art. Examples of identified pharmaceutically acceptable salts are salts of the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, fumaric acid, lactic acid, citric acid, etc.

[0133] "Compound, isomer, racemate, prodrug, deuterated compound or pharmaceutically acceptable salt thereof" means compound or pharmaceutically acceptable salt thereof, isomer or pharmaceutically acceptable salt thereof, racemate or pharmaceutically acceptable salt thereof, prodrug or pharmaceutically acceptable salt thereof, deuterated compound or pharmaceutically acceptable salt thereof.

[0134] "Pharmaceutical composition" means containing one or more of the compounds described herein or their pharmaceutically acceptable salts, isomers or their pharmaceutically acceptable salts, racemates or their pharmaceutically acceptable salts, prodrugs or their pharmaceutically acceptable salts, deuterated compounds or their pharmaceutically acceptable salts, and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and the exertion of its biological activity.

[0135] "Prodrug" refers to a structure that can be converted into a compound of formula (I) in vivo. Such conversion is influenced by the hydrolysis of the prodrug in the blood or by its enzymatic conversion into the parent structure in the blood or tissues.

[0136] In compounds of general formula I, atoms may exhibit their natural isotopic abundances, or one or more atoms may be artificially enriched with specific isotopes having the same atomic number but different atomic masses or mass numbers from those predominantly found in nature. For example, different isotopic forms of hydrogen (H) include protium (¹H), deuterium (²H), and tritium (³H).

[0137] The present invention will be further described below with reference to embodiments. It should be noted that the following embodiments are provided for illustrative purposes only and do not constitute a limitation on the scope of protection claimed by the present invention. Those skilled in the art can prepare the compounds described in this application based on the synthetic routes and experimental methods described in the following embodiments. The compounds can be structurally characterized by analytical means such as 1H-NMR and mass spectrometry, and their activity data can be determined using the bioactivity testing methods described herein.

[0138] Experimental materials and analytical instruments:

[0139] The thin-layer chromatography (TLC) plate model was HSGF-254 (thickness 0.15-0.2mm, produced by Yantai Chemical Experimental Plant); the column chromatography silica gel was commercial 200-300 mesh silica gel produced by Qingdao Marine Chemical Plant.

[0140] 1 H-NMR was recorded using a Bruker Avance III-400 NMR spectrometer with tetramethylsilane (TMS) as the internal standard; chemical shifts were (ppm, δ:), and proton coupling was labeled as singlet (s), doublet (d), triplet (t), quartet (q), and multiplet (m).

[0141] Low-resolution mass spectrometry was recorded using an Agilent 6110 mass spectrometer.

[0142] Abbreviations and annotations:

[0143] DCM: dichloromethane; DMF: N,N-dicarboxamide; THF: tetrahydrofuran; DMSO: dimethyl sulfoxide; DIPEA: N,N-diisopropylethylamine.

[0144] Unless otherwise specified, the raw materials, reagents, and methods used in the examples are all conventional raw materials, reagents, and methods in the art, and the experimental materials and reagents used can be obtained from commercially available channels.

[0145] Unless otherwise specified, all reactions in this invention are carried out under continuous magnetic stirring, in a dry nitrogen or argon atmosphere, using a dry solvent, and the reaction temperature is expressed in degrees Celsius (°C).

[0146] Example 1: Preparation of compound 1-1

[0147] The synthetic route for compound 1-1 is as follows:

[0148] Step 1: Preparation of 4-(dimethylamino)-4-phenylcyclohexane-1-one oxime

[0149] 4-(dimethylamino)-4-phenylcyclohexane-1-one (200 mg, 0.92 mmol) was dissolved in 10 mL of methanol, followed by the addition of 10 mL of an aqueous solution of sodium bicarbonate (230 mg, 2.74 mmol), and the mixture was stirred at room temperature for 15 minutes. Hydroxylamine hydrochloride (130 mg, 1.84 mmol) was then added, and the reaction was continued for 2 hours. The reaction was monitored by TLC until complete. 100 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 220 mg of a colorless oily compound, with a yield of 99.1%. MS m / z calculated value: 232.16; experimental value: 233.1 [M+H] + .

[0150] Step 2: Preparation of N,N-dimethyl-1-phenylcyclohexane-1,4-diamine

[0151] 4-(dimethylamino)-4-phenylcyclohexane-1-one oxime (200 mg, 0.86 mmol) was dissolved in 10 mL of methanol and cooled to 0 °C. Molybdenum trioxide (186 mg, 1.3 mmol) was then added, and the mixture was stirred for 5 minutes. Sodium borohydride (164 mg, 4.3 mmol) was then added in portions. The mixture was allowed to react at room temperature overnight. The reaction was monitored by TLC until complete. The reaction mixture was filtered, the filter cake was washed with methanol, and the filtrate was collected. Sodium hydroxide solution was added to the filtrate, and the filtrate was extracted five times with DCM. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 180 mg of a colorless oily compound, with a yield of 95.9%. MS m / z calculated value: 218.18; experimental value: 219.08 [M+H] + .

[0152] Step 3: Preparation of 2-(2-chloroethyl)benzoyl chloride

[0153] To a 100 mL sealed tube, add isochromatic 1-one (1.0 g, 6.75 mmol), 20 mL of thionyl chloride, and 0.5 mL of DMF. React at 80 °C for 24 h. TLC monitoring showed the reaction was complete. The system was then directly concentrated under reduced pressure to give 1.3 g of a pale yellow oily compound, with a yield of 98.2%. MS m / z calculated value: 202.00; experimental value: 203.1 [M+H] + .

[0154] Step 4: Preparation of 2-(2-chloroethyl)-N-(4-(dimethylamino)-4-phenylcyclohexyl)benzamide

[0155] N,N-Dimethyl-1-phenylcyclohexane-1,4-diamine (190 mg, 0.87 mmol) was dissolved in 20 mL of DCM and cooled to 0 °C. Then, DIPEA (530 mg, 4.1 mmol) was added, followed by the addition of a DCM solution of 2-(2-chloroethyl)benzoyl chloride (160 mg, 0.78 mmol) over 5 minutes. The reaction was continued for 2 hours. The reaction was monitored by TLC until complete. 100 mL of H₂O was added, and the mixture was extracted with dichloromethane (100 mL × 3). The organic phases were combined, concentrated under reduced pressure, and the residue was purified by column chromatography to give 110 mg of a colorless oily compound, with a yield of 33.2%. MS m / z calculated value: 384.20; experimental value: 385.1 [M+H] + .

[0156] Step 5: Preparation of 2-(4-(dimethylamino)-4-phenylcyclohexyl)-3,4-dihydroisoquinoline-1(2H)-one

[0157] 2-(2-chloroethyl)-N-(4-(dimethylamino)-4-phenylcyclohexyl)benzamide (100 mg, 0.26 mmol) was dissolved in 20 mL of anhydrous THF and cooled to 0 °C. Potassium tert-butoxide (58 mg, 0.52 mmol) was then added, and the mixture was allowed to react overnight at room temperature. The reaction was monitored by TLC until complete. 100 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 60 mg of a white solid, with a yield of 66.3%. MS m / z calculated value: 348.22; experimental value: 349.35 [M+H] + .

[0158] 1 H NMR (400MHz, DMSO-d6) δ7.90–7.84(m,1H),7.50–7.42(m,1H),7.39–7.34(m,5H),7.31–7.24(m,2H),4.59(ddt,J=12.5,8. 4,4.3Hz,1H),3.47(t,J=6.4Hz,2H),2.94(t,J=6.4Hz,2H),2.78(d,J=13.2Hz,2H),2.07–1.93(m,8H),1.53–1.39(m,4H).

[0159] Example 2: Preparation of compounds 1-2

[0160] The synthetic routes for compounds 1-2 are as follows:

[0161] Step 1: Preparation of N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine)

[0162] To a mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (300 mg, 1.38 mmol) and o-diphenylamine (300 mg, 2.76 mmol), 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid were added, and the mixture was stirred for 10 min. Then, sodium triacetoxyborohydride (880 mg, 4.15 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 300 mg of a pale yellow oily compound, with a yield of 70.2%. MS m / z calculated value: 309.22; experimental value: 310.35 [M+H] + .

[0163] Step 2: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0164] CDI (190 mg, 1.16 mmol) was added in a single batch to a solution of N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine (300 mg, 0.97 mmol) in acetonitrile (50 mL), and the mixture was allowed to react overnight at room temperature. The reaction was monitored by TLC until complete. A saturated sodium bicarbonate solution (100 mL) was added to the mixture, and the mixture was filtered. The filter cake was washed three times with ethyl acetate (50 mL) and three times with H₂O (50 mL). The filter cake was collected and dried to give 120 mg of a white solid compound, with a yield of 37%. MS m / z calculated value: 335.20; experimental value: 336.32 [M+H] + .

[0165] Step 3: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-3-ethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0166] 50 mL of DMF was added to a mixture of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (120 mg, 0.36 mmol) and cesium carbonate (240 mg, 0.72 mmol), followed by the addition of iodoethane (62 mg, 0.39 mmol). The reaction was carried out at 100 °C for 12 h. The reaction was monitored by TLC until complete. 100 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 92 mg of a white solid, with a yield of 70.3%. MS m / z calculated value: 363.23; experimental value: 364.32 [M+H] + .

[0167] 1 H NMR (400MHz, DMSO-d6) δ7.52–7.32(m,5H),7.11(d,J=7.8Hz,1H),6.94(t,J=7.7Hz,1H),6.73(td,J=7.8,1.2Hz,1H),6.26(d,J=7.9H z,1H),4.38–4.27(m,1H),3.78(q,J=7.1Hz,2H),2.78(d,J=12.8Hz,2H),2.04–1.92(m,8H),1.77–1.59(m,4H),1.13(t,J=7.1Hz,3H).

[0168] Example 3: Preparation of compounds 1-3

[0169] The synthetic routes for compounds 1-3 are as follows:

[0170] Step 1: Preparation of methyl 2-(2-nitrophenyl)butyrate

[0171] A mixture of methyl 2-(2-nitrophenyl)acetate (1.0 g, 5.1 mmol), potassium carbonate (5.7 g, 41 mmol), and iodoethane (1.0 g, 6.1 mmol) was reacted with 50 mL of acetonitrile and 0.5 mL of 18-crown ether-6 at 100 °C for 36 h. The reaction was monitored by TLC until complete. 100 mL of ethyl acetate was added, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 540 mg of a pale yellow solid, with a yield of 47.4%. MS m / z calculated value: 223.08; experimental value: 224.32 [M+H] + .

[0172] Step 2: Preparation of methyl 2-(2-aminophenyl)butyrate

[0173] Palladium / carbon (10 wt%, 54 mg) was added to a methanol (50 mL) solution of methyl 2-(2-nitrophenyl)butyrate (540 mg, 2.42 mmol), and the reaction was carried out under a hydrogen balloon atmosphere for 3 h. The reaction was monitored by TLC until complete. The mixture was filtered, and the filtrate was collected and concentrated directly under reduced pressure to give 450 mg of a pale yellow oily compound, with a yield of 85.5%. MS m / z calculated value: 193.25; experimental value: 194.32 [M+H] + .

[0174] Step 3: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-3-ethylindole-2-one

[0175] To a mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (300 mg, 1.38 mmol) and methyl 2-(2-aminophenyl)butyrate (400 mg, 2.07 mmol), 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid were added, and the mixture was stirred for 10 min. Then, sodium triacetoxyborohydride (880 mg, 4.15 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 130 mg of a pale yellow oily compound, with a yield of 26.5%. MS m / z calculated value: 362.24; experimental value: 363.31 [M+H] + .

[0176] 1 H NMR (400MHz, DMSO-d6) δ7.59–7.33(m,5H),7.25–7.19(m,1H),6.90(dd,J=5. 6,3.2Hz,2H),6.12(d,J=6.2Hz,1H),4.25(dq,J=12.3,6.3,5.1Hz,1H),3.36( t,J=5.4Hz,1H),2.78(d,J=13.0Hz,2H),2.25–1.92(m,8H),1.82(dh,J=13.6, 6.8Hz,2H),1.76–1.64(m,2H),1.53(t,J=14.9Hz,2H),0.61(t,J=7.4Hz,3H).

[0177] Example 4: Preparation of compounds 1-4

[0178] Preparation of compounds 1-4

[0179] The preparation of compounds 1-4 was similar to that in Example 3, except that methyl 2-(2-nitrophenyl)butyrate in step 2 was replaced with methyl 2-(2-nitrophenyl)acetate, yielding 30 mg of pale yellow powder of compounds 1-4, with a yield of 45.8%.

[0180] 1 H NMR (400MHz, DMSO-d6) δ7.49(t,J=7.5Hz,2H),7.43(d,J=7.7Hz,2H),7.38(t,J= 7.2Hz,1H),7.20–7.15(m,1H),6.90–6.84(m,2H),6.10–6.04(m,1H),4.28(td,J= 12.3,6.0Hz,1H),3.44(s,2H),2.78(d,J=13.0Hz,2H),2.00(d,J=8.6Hz,6H),1. 94(dd,J=13.1,3.0Hz,2H), 1.69(t,J=13.3Hz,2H), 1.54(dd,J=13.3,4.6Hz,2H).

[0181] Example 5: Preparation of compounds 1-6

[0182] The synthetic routes for compounds 1-6 are as follows:

[0183] Step 1: Preparation of N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine)

[0184] To a mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (300 mg, 1.38 mmol) and o-diphenylamine (300 mg, 2.76 mmol), 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid were added, and the mixture was stirred for 10 min. Then, sodium triacetoxyborohydride (880 mg, 4.15 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 300 mg of a pale yellow oily compound, with a yield of 70.2%. MS m / z calculated value: 309.22; experimental value: 310.35 [M+H] + .

[0185] Step 2: Preparation of tert-butyl 3-(1-(4-(dimethylamino)-4-phenylcyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylic acid

[0186] N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine (200 mg, 0.65 mmol) and sodium metabisulfite (373 mg, 1.94 mmol) were added separately to 100 mL Shrek tubes and purged three times with nitrogen. Then, 20 mL of an N,N-dimethylformamide solution containing N-tert-butyloxycarbonyl-3-piperidinone (257 mg, 1.29 mmol) was added to the Shrek tube, and the system temperature was maintained at 110 °C. The reaction was monitored by TLC until complete. 150 mL of ethyl acetate was added to the system, and the mixture was washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate, and the residue was concentrated under reduced pressure and purified by column chromatography to give 105 mg of a pale yellow oily compound, with a yield of 32.2%. MS m / z calculated value: 502.33; experimental value: 503.33 [M+H] + .

[0187] Step 3: Preparation of N,N-dimethyl-1-phenyl-4-(2-(piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)cyclohexane-1-amine

[0188] 105 mg (0.21 mmol) of 3-(1-(4-(dimethylamino)-4-phenylcyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester and 10 mL of ethyl acetate solution of hydrochloric acid were added to a 100 mL round-bottom flask. The mixture was stirred at room temperature for 2 hours. After the reaction was completed by TLC, the mixture was concentrated under reduced pressure. The crude product was purified by slurrying with dichloromethane to give 71 mg of white solid compound (1-6), with a yield of 85.5%.

[0189] 1 H NMR(400MHz, CDCl3)δ7.80(s,1H),7.74(dd,J=6.1,3.2Hz,1H),7.45–7.34(m,5H),7.31(t,J=7.0Hz,2H),5.12(s,1H),4.40–4.24( m,2H),3.26(q,J=6.3Hz,2H),3.02(t,J=7.4Hz,2H),2.94–2.79(m,6H),2.19(s,6H),2.05(q,J=7.0Hz,4H),1.79(d,J=11.7Hz,2H).

[0190] Example 6: Preparation of compounds 1-10

[0191] The synthetic routes for compounds 1-10 are as follows:

[0192] Step 1: Preparation of tert-butyl(2-((4-(dimethylamino)-4-phenylcyclohexyl)amino)-4-fluorophenyl)carbamate

[0193] A mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (300 mg, 1.38 mmol) and tert-butyl(2-amino-4-fluorophenyl)carbamate (300 mg, 1.33 mmol) was added to 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid, and stirred for 10 min. Then, sodium triacetoxyborohydride (843 mg, 3.98 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 86 mg of a yellowish-brown oily compound, with a yield of 15.3%. MS m / z calculated value: 427.26; experimental value: 428.27 [M+H] + .

[0194] Step 2: N 1 Preparation of 1,2-(4-(dimethylamino)-4-phenylcyclohexyl)-5-fluorobenzene-1,2-diamine

[0195] 86 mg (0.20 mmol) of tert-butyl(2-((4-(dimethylamino)-4-phenylcyclohexyl)amino)-4-fluorophenyl)carbamate was dissolved in 5 mL of ethyl acetate, followed by the addition of 2 mL of ethyl acetate hydrochloride solution (4 M). The reaction was allowed to proceed at room temperature for 3 h. The reaction was monitored by TLC until complete. 10 mL of saturated sodium bicarbonate solution was added to the system, and the mixture was extracted three times with DCM. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 54 mg of a yellowish-brown oily compound, with a yield of 81.8%. MS m / z calculated value: 327.21; experimental value: 328.22 [M+H] + .

[0196] Step 3: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-5-fluoro-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0197] To N 1 CDI (31 mg, 0.50 mmol) was added in a single batch to a solution of 54 mg (0.17 mmol) of 4-(dimethylamino)-4-phenylcyclohexyl)-5-fluorobenzene-1,2-diamine in acetonitrile (5 mL), and the mixture was reacted overnight at room temperature. The reaction was monitored by TLC until complete. A saturated sodium bicarbonate solution (10 mL) was added to the mixture, and the mixture was filtered. The filter cake was washed three times with acetonitrile (10 mL) and dried to give 54 mg of a white solid compound, with a yield of 93.1%.

[0198] 1H NMR (400MHz, DMSO-d6) δ10.94(s,1H),7.43(ddd,J=26.3,16.7,7.3Hz,5H),6.76(d,J=8.7Hz,1H),6.51(t, J=9.1Hz,1H),6.08(d,J=8.8Hz,1H),4.26(s,1H),2.77(d,J=12.8Hz,2H),1.98(s,8H),1.77–1.53(m,4H).

[0199] Example 7: Preparation of compounds 1-18

[0200] The preparation method of compounds 1-18 was similar to that in Example 2, except that iodoethane in step 3) was replaced with an equimolar amount of 4-(bromomethyl)-2,2-dimethyl-1,3-dioxolane, followed by deprotection with hydrogen chloride-ethyl acetate solution to obtain 81 mg of a white solid compound, with a yield of 55.4%. MS m / z calculated value: 409.24; experimental value: 410.24 [M+H] + .

[0201] 1 H NMR (400MHz, DMSO) δ7.38 (d, J = 3.7Hz, 4H), 7.36–7.29 (m, 1H), 7.30–7.25 (m, 1H), 7.24–7.18 ( m,1H),7.10–7.00(m,2H),4.94(d,J=5.0Hz,1H),4.71(t,J=5.8Hz,1H),4.37(d,J=12.8Hz,1H) ,3.93–3.85(m,1H),3.76(dq,J=13.1,7.0Hz,2H),3.37(t,J=5.2Hz,2H),2.81(d,J=13.4Hz,2H ),2.63(dd,J=23.6,11.4Hz,2H),2.06(s,6H),1.57(d,J=13.4Hz,2H),1.50(d,J=13.3Hz,2H).

[0202] Example 8: Preparation of compounds 1-19

[0203] The synthetic routes for compounds 1-19 are as follows:

[0204] Step 1: Preparation of tert-butyl(2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethyl)(methyl)carbamate

[0205] The preparation of compound 2 was similar to that of Example 2, except that iodoethane in step 3 was replaced with tert-butyl(2-chloroethyl)(methyl)carbamate, yielding 150 mg of a pale yellow powder in a yield of 68.4%. MS m / z calculated value: 492.66; experimental value: 493.81 [M+H] + .

[0206] Step 2: Preparation of compound 1-(4-(dimethylamino)-4-phenylcyclohexyl)-3-(2-(methylamino)ethyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one.

[0207] The compound tert-butyl(2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethyl)(methyl)carbamate (150 mg, 0.3 mmol) and sodium iodide (179 mg, 1.2 mmol) were dissolved in 15 mL of acetonitrile. The mixture was heated to 85 °C, and 0.2 mL of TMS-Cl was added under N2 protection. The reaction was monitored by TLC until complete. Sodium bicarbonate was added to adjust the pH to alkaline. The mixture was washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate. The residue obtained by concentration under reduced pressure was purified by column chromatography to give 105 mg of compound 1-19 as a white powder, with a yield of 87.7%.

[0208] 1 H NMR (400MHz, DMSO-d6) δ7.40–7.37(m,4H),7.36–7.33(m,1H),7.28(dt,J=5.0,3.4H z,1H),7.25(dd,J=7.2,1.8Hz,1H),7.08(tt,J=7.5,6.0Hz,2H),4.38(ddd,J=17.1,1 2.3,4.9Hz,1H),3.99(t,J=6.2Hz,2H),2.97(t,J=6.2Hz,2H),2.81(d,J=13.4Hz,2H) ,2.65–2.53(m,2H),2.43(s,3H),2.06(s,6H),1.64–1.57(m,3H),1.57–1.47(m,2H).

[0209] Example 9: Preparation of compounds 1-20

[0210] The preparation of compounds 1-20 was similar to that in Example 2, except that 4-(dimethylamino)-4-phenylcyclohexane-1-one in step 1 was replaced with 4-(dimethylamino)-4-(3-fluorophenyl)cyclohexane-1-one, yielding 34 mg of pale yellow solid of compound 1-20, with a yield of 43%.

[0211] 1 H NMR (400MHz, CDCl3) δ7.52(q,J=7.4Hz,1H),7.26(d,J=7.9Hz,1H),7.17(d,J=1 0.5Hz,2H),7.04–6.95(m,2H),6.85(t,J=7.7Hz,1H),6.34(s,1H),4.57–4.45( m,1H),3.91(q,J=7.2Hz,2H),2.80(d,J=12.9Hz,2H),2.37–2.20(m,6H),2.21– 2.09(m,2H),2.05-1.99(m,2H),1.87(d,J=12.7Hz,2H),1.32(t,J=7.2Hz,3H).

[0212] Example 10: Preparation of compounds 1-23

[0213] The preparation method of compounds 1-23 was similar to that in Example 2, except that iodoethane in step 3) was replaced with an equimolar amount of 2-iodo-N-methylacetamide, yielding 146 mg of a white solid compound in a yield of 83.0%. MS m / z calculated value: 406.24; experimental value: 407.24 [M+H] + .

[0214] 1 H-NMR (400MHz, DMSO-d6) δ8.10(q,J=4.7Hz,1H),7.43–7.36(m,4H),7.34(d,J=7.9Hz,1H),7.27(tt,J=5.7,2.7Hz,1H),7.12–6.99(m,3H) ,4.43(s,2H),4.36(dq,J=11.0,5.7Hz,1H),2.81(d,J=13.5Hz,2H),2.69–2.54(m,5H),2.07(s,6H),1.65–1.57(m,2H),1.55–1.47(m,2H).

[0215] Example 11: Preparation of compounds 1-25

[0216] The synthetic route for compounds 1-25 is as follows:

[0217] Step 1: Preparation of 2-(4-(dimethylamino)-4-phenylcyclohexyl)isoindoline-1-one

[0218] N,N-dimethyl-1-phenylcyclohexane-1,4-diamine (50 mg, 0.23 mmol) and methyl 2-(bromomethyl)benzoate (75 mg, 0.27 mmol) were dissolved in 10 mL of tetrahydrofuran, heated under reflux overnight, and the reaction was monitored by TLC until complete. The mixture was concentrated under reduced pressure and column chromatography to give a colorless oily compound 1-25 17 mg, with a yield of 22.1%.

[0219] 1 H NMR (400MHz, CDCl3) δ7.88(d,J=7.5Hz,1H),7.57–7.46(m,2H),7.46–7.41(m,1H),7.39(d,J=6.4Hz,4H),7.26(d,J=2.5Hz,1H) ,4.49(td,J=8.4,4.3Hz,1H),4.38(s,2H),2.28(dq,J=14.4,4.9Hz,2H),2.04(ddt,J=14.1,9.6,4.9Hz,4H),1.92–1.74(m,8H).

[0220] Example 12: Preparation of compounds 1-35

[0221] The synthetic route for compounds 1-35 is as follows:

[0222] Step 1: 4,5-Dichloro-N 1 Preparation of 1,2-(4-(dimethylamino)-4-phenylcyclohexyl)phenyl-1,2-diamine

[0223] To a mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (300 mg, 1.38 mmol) and 4,5-dichlorophenyl-1,2-diamine (244 mg, 1.38 mmol), 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid were added, and the mixture was stirred for 10 min. Then, sodium triacetoxyborohydride (878 mg, 4.14 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 M, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 190 mg of a yellowish-brown oily compound, with a yield of 36.5%. MS m / z calculated value: 377.14; experimental value: 378.15 [M+H] + .

[0224] Step 2: Preparation of 5,6-dichloro-1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0225] To 4,5-dichloro-N1 CDI (129 mg, 0.79 mmol) was added in a single dose to a solution of 100 mg (0.26 mmol) of 4-(dimethylamino)-4-phenylcyclohexyl)phenyl-1,2-diamine in 10 mL of acetonitrile. The reaction was allowed to proceed overnight at room temperature. The reaction was monitored by TLC until complete. A saturated sodium bicarbonate solution (20 mL) was added to the system, and the mixture was filtered. The filter cake was washed three times with acetonitrile (10 mL) and dried to give 64 mg of a white solid, yielding 60.4%. MS m / z calculated value: 403.12; experimental value: 404.13 [M+H] + .

[0226] Step 3: Preparation of 5,6-dichloro-1-(4-(dimethylamino)-4-phenylcyclohexyl)-3-ethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0227] 5 mL of DMF was added to a mixture of 5,6-dichloro-1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (64 mg, 0.16 mmol) and cesium carbonate (103 mg, 0.48 mmol), followed by the addition of iodoethane (50 mg, 0.48 mmol). The reaction was carried out at room temperature for 12 h. The reaction was monitored by TLC until complete. 20 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by thin-layer chromatography to give compound 1-35 as a white solid (30 mg), with a yield of 44.8%.

[0228] 1 H NMR (400MHz, CDCl3) δ7.52(t,J=7.4Hz,2H),7.40(t,J=6.4Hz,3H),6.95(s,1H),6.08(s,1H),4.47(m,1H),3.82(q, J=7.2Hz,2H),2.88–2.73(m,2H),2.17(s,6H),2.00(m,2H),1.87(d,J=13.6Hz,2H),1.80–1.71(m,2H),1.26(s,3H).

[0229] Example 13: Preparation of compounds 1-37

[0230] Step 1: Preparation of 4-(3,4-dihydroisoquinoline-2(1H)-yl)-N,N-dimethyl-1-phenylcyclohexane-1-amine

[0231] To a mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (200 mg, 0.92 mmol) and 1,2,3,4-tetrahydroisoquinoline (244 mg, 1.84 mmol), 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid were added, and the mixture was stirred for 10 min. Then, sodium triacetoxyborohydride (585 mg, 2.76 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 25 mg of a pale yellow oily compound, with a yield of 8.1%. MS m / z calculated value: 334.24; experimental value: 335.31 [M+H] + .

[0232] 1 H NMR(400MHz, DMSO-d6)δ7.45–7.33(m,4H),7.28(t,J=6.9Hz,1H),7.04(dq,J=7 .9,3.7Hz,3H),7.00–6.96(m,1H),3.57(s,2H),3.03(dd,J=7.3,5.6Hz,1H),2. 68(d,J=5.2Hz,2H),2.61(d,J=5.9Hz,2H),1.97(d,J=3.4Hz,6H),1.91(s,1H), 1.85(d,J=12.3Hz,2H),1.77(s,1H),1.60(t,J=12.7Hz,2H),1.18–1.08(m,2H).

[0233] Example 14: Preparation of compounds 1-38

[0234] At room temperature, PCl5 (93 mg, 0.44 mmol) was slowly added to an acetonitrile solution of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (100 mg, 0.29 mmol), and the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by TLC until complete. The pH was adjusted to neutral by adding 50 mL of saturated sodium bicarbonate solution. 150 mL of ethyl acetate was added, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 70 mg of a colorless oily compound, with a yield of 66.6%. MS m / z calculated value: 353.16; experimental value: 355.16 [M+H] + .

[0235] 1H NMR (400MHz, DMSO-d6) δ7.37(d,J=4.4Hz,5H),7.28(d,J=7.2Hz,2H),7.00(d,J=10.3Hz,2H),4.32(s,1H ), 2.80 (d, J = 13.2Hz, 2H), 2.57 (d, J = 13.1Hz, 2H), 2.06 (d, J = 5.4Hz, 6H), 1.51 (dd, J = 27.9, 13.3Hz, 4H).

[0236] Example 15: Preparation of compounds 1-39

[0237] The preparation method of compound 1-39 is similar to that of Example 1, except that the isochromic 1-one in step 3 is replaced with an equimolar amount of 7-chloro-isochromic 1-one, to obtain 55 mg of white solid compound 1-39, with a yield of 52.0%.

[0238] 1 H NMR (400MHz, DMSO-d6) δ7.81(d,J=2.3Hz,1H),7.53(dd,J=8.1,2.4Hz,1H),7.36(d,J=4.7Hz,5H),7.26(q,J=4.8,4.3Hz,1H) ,3.77(d,J=24.6Hz,1H),3.51–3.44(m,2H),2.94(t,J=6.4Hz,2H),2.03–1.96(m,8H),1.74–1.55(m,2H),1.48–1.38(m,4H).

[0239] Example 16: Preparation of compounds 1-40

[0240] The preparation method of compound 1-40 is similar to that of Example 1, except that the isochromic 1-one in step 3 is replaced with an equimolar amount of 7-methoxy-isochromic 1-one, to obtain 88 mg of white solid compound 1-40, with a yield of 82.0%.

[0241] 1H NMR (400MHz, DMSO-d6) δ7.97–7.81(m,1H),7.55–7.49(m,1H),7.40–7.32(m,5H),7.28–7.24(m,1H),4.69(m,1H),3.6 7(s,3H),3.48(t,J=6.4Hz,2H),2.94(t,J=6.4Hz,2H),2.79(d,J=13.2Hz,2H),2.11–1.95(m,8H),1.55–1.45(m,4H).

[0242] Example 17: Preparation of compounds 1-41

[0243] The synthetic route for compounds 1-41 is as follows:

[0244] Step 1: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,4-dihydroquinoxaline-2,3-dione

[0245] The product N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine (100 mg, 0.32 mmol), monomethyl oxalyl chloride (53 mg, 0.38 mmol), and dichloromethane (20 mL) from step 1 of Example 2 were added to a gai-shaped flask, followed by the slow addition of triethylamine (100 mg, 0.99 mmol). The system was then reacted at room temperature for 24 h. The reaction was monitored by TLC until complete. The system was concentrated and passed through a column to give a pale yellow solid compound 1-41 35 mg, with a yield of 28%.

[0246] 1 H NMR(400MHz,DMSO-d6)δ12.01(s,1H),7.47–7.33(m,5H),7.29(td,J=6.4,6.0,2.8Hz,1H),7.2 3–7.14(m,3H),2.79(t,J=16.9Hz,4H),2.07(s,6H),2.05–2.00(m,1H),1.57(t,J=12.9Hz,4H).

[0247] Example 18: Preparation of compounds 1-42

[0248] The preparation of compound 1-(4-(dimethylamino)-4-phenylcyclohexyl)-3-isopropyl-1,3-dihydro-2H-benzo[d]imidazol-2-one was similar to that in Example 2, except that iodoethane in step 3 was replaced with 2-iodopropane, yielding 80 mg of compound 1-42 white powder, with a yield of 85.4%.

[0249] 1 H NMR(400MHz, DMSO-d6)δ7.40(d,J=4.4Hz,4H),7.38–7.32(m,2H),7.29(s,1H),7.11–7.02(m,2H),4.64(p,J=6.9Hz,1H),4.3 7(d,J=13.1Hz,1H),2.82(d,J=13.5Hz,2H),2.67–2.55(m,2H),2.08(s,6H),1.59(s,2H),1.53(s,2H),1.47(d,J=7.0Hz,6H).

[0250] Example 19: Preparation of compounds 1-43

[0251] The preparation method of compound 1-43 is similar to that of Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of 1-iodo-2-methylpropaneisobutane to obtain 95 mg of white solid compound 1-43, with a yield of 41.3%.

[0252] 1 H NMR(400MHz, DMSO-d6)δ7.40(d,J=4.4Hz,4H),7.38–7.32(m,2H),7.29(s,1H),7.11–7.02(m,2H),4.64(p,J=6.9Hz,1H),4.37( d,J=13.1Hz,1H),2.82(d,J=13.5Hz,2H),2.67–2.55(m,2H),2.08(s,6H),1.59(s,2H),1.53(s,2H),1.48(s,3H),1.46(s,3H).

[0253] Example 20: Preparation of compounds 1-44

[0254] Step 1: Preparation of 1-cyclopropyl-3-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0255] Under a nitrogen atmosphere, a solution (5 mL) of 2,2'-bipyridine (93 mg, 0.60 mmol) and copper acetate (108 mg, 0.60 mmol) in 1,2-dichloroethane was heated to 70 °C and after 5 min, it was poured into a solution (5 mL) of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (200 mg, 0.60 mmol), cyclopropylboronic acid (102 mg, 1.20 mmol), and sodium carbonate (126 mg, 1.20 mmol) in 1,2-dichloroethane and heated to 70 °C. After 2 h, the reaction was monitored by TLC until complete. 20 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and the residue was concentrated under reduced pressure and purified by column chromatography to give a white solid compound 1-44 100 mg, with a yield of 44.8%.

[0256] 1 H NMR(400MHz,DMSO-d6)δ7.39(d,J=4.3Hz,4H),7.35–7.30(m,1H),7.30–7.27 (m,1H),7.26–7.20(m,1H),7.14–7.04(m,2H),4.36(t,J=8.7Hz,1H),2.89(t t,J=6.9,3.6Hz,1H),2.80(d,J=13.4Hz,2H),2.66–2.53(m,2H),2.06(s,6H) ,1.53(q,J=11.7Hz,4H), 1.03(dd,J=7.4,5.2Hz,2H), 0.90(q,J=3.8Hz,2H).

[0257] Example 21: Preparation of compounds 1-45

[0258] The preparation method of compound 1-45 is similar to that of Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of iodomethylcyclopropane, to obtain 115 mg of white solid compound 1-45, with a yield of 71.0%.

[0259] 1H NMR(400MHz,DMSO-d6)δ7.43–7.36(m,4H),7.36(s,1H),7.31–7.23(m,2H), 7.12–7.01(m,2H),4.47–4.29(m,1H),3.72(d,J=7.0Hz,2H),2.81(d,J=13. 4Hz,2H),2.60(q,J=12.1Hz,2H),2.06(s,6H),1.57(d,J=15.2Hz,2H),1.50 (d,J=13.3Hz,2H),1.21–1.12(m,1H),0.51–0.43(m,2H),0.40–0.34(m,2H).

[0260] Example 22: Preparation of compounds 1-46

[0261] The preparation method of compound 1-46 is similar to that of Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of bromoacetonitrile, to obtain 20 mg of white solid compound 1-46, with a yield of 17.9%.

[0262] 1 H NMR (400MHz, CDCl3) δ7.50–7.45(m,1H),7.43–7.33(m,4H),7.30(d,J=6.7Hz,1H),7.23–7.11(m,3H),4.84(s,2H),4.51 (m,1H),3.57(s,2H),2.81(d,J=13.7Hz,2H),2.69(q,J=13.2Hz,2H),2.15(s,6H),1.80–1.70(m,2H),1.65–1.56(m,2H).

[0263] Example 23: Preparation of compounds 1-47

[0264] The preparation method of compounds 1-47 is similar to that of Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of 2-bromo-1-cyclopropylethyl ketone, yielding 105 mg of white solid compound with a yield of 65.5%.

[0265] 1H NMR (400MHz, DMSO-d6) δ7.43–7.38 (m, 4H), 7.37 (d, J = 7.6Hz, 1H), 7.29 (ddd, J=8.4,5.7,3.3Hz,1H),7.13–7.00(m,3H),4.98(s,2H),4.46–4.32(m,1H),2. 83(d,J=13.4Hz,2H),2.71–2.55(m,2H),2.26–2.15(m,1H),2.08(s,6H),1.67 –1.46(m,4H),1.02(ddt,J=7.9,6.1,2.7Hz,2H),0.94(dh,J=4.4,2.1Hz,2H).

[0266] Example 24: Preparation of compounds 1-48

[0267] The preparation method of compound 1-48 is similar to that of Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of propionyl chloride, yielding 22 mg of white solid compound 1-48, with a yield of 18.9%.

[0268] 1 H NMR (400MHz, CDCl3) δ8.17(d,J=8.1Hz,1H),7.53(t,J=7.6Hz,2H),7.44(d,J =7.4Hz,3H),7.01(t,J=7.9Hz,1H),6.86(t,J=7.8Hz,1H),6.12(d,J=8.0Hz,1 H),4.50(dt,J=12.4,7.1Hz,1H),3.13(q,J=7.3Hz,2H),2.86(d,J=12.7Hz,2 H),2.23(s,6H),2.19–2.07(m,4H),1.84–1.77(m,2H),1.22(d,J=7.3Hz,3H).

[0269] Example 25: Preparation of compounds 1-49

[0270] The synthetic routes for compounds 1-49 are as follows:

[0271] Step 1: Preparation of methyl 2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetate

[0272] The preparation of methyl 2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetate was similar to step 3 in Example 3, except that iodoethane was replaced with methyl bromoacetate in Example 3. 85 mg of a pale yellow solid was obtained, which could be used in the next reaction without further purification, with a yield of 52%. MS m / z calculated value: 407.22; experimental value: 408.23 [M+H] + .

[0273] Step 2: Preparation of 2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetamide

[0274] 2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetate (85 mg, 0.21 mmol) was dissolved in 10 mL of methanol solution containing 2N ammonia and reacted at room temperature for 10 h. The reaction was monitored by TLC until complete. The solution was concentrated under reduced pressure and column chromatography to give 71 mg of a pale yellow solid, with a yield of 86%.

[0275] 1 H NMR(400MHz, CDCl3)δ7.58–7.30(m,7H),7.22–7.13(m,2H),7.10(dd,J=7.4,1.9Hz,1H),6 .27(s,1H),5.52(s,1H),4.53(s,2H),3.01–2.66(m,4H),2.20(s,6H),1.86–1.65(m,4H).

[0276] Example 26: Preparation of compounds 1-50

[0277] The preparation method of compounds 1-50 is similar to that of Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of 2-iodo-N,N-dimethylacetamide, yielding 140 mg of white solid compound with a yield of 84.2%.

[0278] 1H NMR(400MHz, DMSO-d6)δ7.38(d,J=3.2Hz,4H),7.36–7.31(m,1H),7.28(dq,J=5.4,2.8Hz,1H),7.06(s,1H),7.11–6.97(m,2H) ,4.73(s,2H),4.37(dq,J=12.2,6.1Hz,1H),3.10(s,3H),2.84(s,5H),2.61(q,J=12.7Hz,2H),2.06(s,6H),1.61–1.47(m,4H).

[0279] Example 27: Preparation of compounds 1-51

[0280] The synthetic route for compounds 1-51 is as follows:

[0281] The preparation method of the compound, steps 1-3, is similar to that in Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of 1-Boc-3-iodoazacyclobutane, yielding 73 mg of a white solid compound in a yield of 61.0%. MS m / z calculated value: 490.29; experimental value: 491.30 [M+H] +

[0282] Step 4: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-3-azacyclobutane-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0283] 73 mg (0.15 mmol) of 3-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)azacyclobutane-1-carboxylic acid tert-butyl ester and 10 mL of ethyl acetate solution of hydrochloric acid were added to a 100 mL round-bottom flask. The mixture was stirred at room temperature for 2 hours. After the reaction was completed by TLC, the mixture was concentrated under reduced pressure. The crude product was purified by slurrying with dichloromethane to give a white solid compound 1-51-61 mg, with a yield of 80.1%.

[0284] 1H NMR(400MHz, DMSO-d6)δ9.43(d,J=72.1Hz,2H),8.07(d,J=6.8Hz,1H),7.70–7.61(m,2H),7.4 7(d,J=6.4Hz,3H),7.39(d,J=7.6Hz,1H),7.03(p,J=7.4Hz,2H),5.33(p,J=8.2Hz,1H),4.63( dt,J=15.2,7.5Hz,2H),4.33(tt,J=9.5,3.7Hz,1H),4.20(dd,J=11.5,6.7Hz,2H),3.11(d,J= 14.7Hz,2H),2.69–2.53(m,2H),2.49(d,J=4.7Hz,6H),2.24–2.09(m,2H),1.77–1.66(m,2H).

[0285] Example 28: Preparation of compounds 1-52

[0286] Step 1: Preparation of compound 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0287] The preparation of this intermediate compound was similar to that in Example 2, except that iodoethane in step 3 was replaced with tert-butyl(2-iodoethoxy)dimethylsilane, yielding 75 mg of a pale yellow powder in 75.2% yield. MS m / z calculated value: 493.77; experimental value: 494.54 [M+H] + .

[0288] Step 2: Preparation of compound 1-(4-(dimethylamino)-4-phenylcyclohexyl)-3-(2-hydroxyethyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one.

[0289] Compound 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one was dissolved in 10 mL of hydrochloric acid in a 1,4-dioxane solution. The reaction was monitored by TLC until complete. The pH was adjusted to alkaline by adding sodium bicarbonate. The mixture was washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate. The residue obtained by concentration under reduced pressure was purified by column chromatography to give 55 mg of compound 1-52 as a white powder, with a yield of 95.2%.

[0290] 1H NMR (400MHz, DMSO-d6) δ7.42–7.35(m,4H),7.35–7.31(m,1H),7.28(dq,J=5.4,2.7,2.2 Hz,1H),7.25–7.18(m,1H),7.11–7.01(m,2H),4.88(t,J=5.6Hz,1H),4.38(td,J=11.8,1 1.4,6.0Hz,1H),3.87(t,J=5.8Hz,2H),3.64(q,J=5.7Hz,2H),2.81(d,J=13.4Hz,2H),2. 59(q,J=12.2,11.5Hz,2H),2.06(s,6H),1.57(d,J=14.8Hz,2H),1.50(d,J=12.5Hz,2H).

[0291] Example 29: Preparation of compounds 1-53

[0292] The preparation method of compounds 1-53 was similar to that of Example 2, except that iodoethane in step 3 was replaced with an equimolar amount of methyl propylene oxide, yielding 47 mg of a white solid compound in a yield of 56.3%. MS m / z calculated value: 309.22; experimental value: 310.35 [M+H] + .

[0293] 1 H NMR (400MHz, CDCl3-d) δ7.50–7.45(m,1H),7.42–7.26(m,5H),7.15–7.09(m,3H),4.55(tt,J=12.3,5.0Hz,1H),3.90(s,2H),3.68( s,1H),2.85–2.76(m,2H),2.70(td,J=12.9,3.2Hz,2H),2.16(s,6H),1.82–1.71(m,2H),1.60(td,J=13.6,3.5Hz,2H),1.32(s,6H).

[0294] Example 30: Preparation of compounds 1-54

[0295] The preparation method of compounds 1-54 is similar to that of Example 2, except that: iodoethane in step 3 is replaced with an equimolar amount of (S)-4-(bromomethyl)-2,2-dimethyl-1,3-dioxolane, and then deprotected by hydrogen chloride-ethyl acetate solution to obtain 100 mg of white solid compound, with a yield of 61.2%.

[0296] 1H NMR (400MHz, DMSO-d6) δ7.43–7.36(m,4H),7.36–7.30(m,1H),7.30–7.25(m,1H),7.22(dd,J=7.1 ,1.9Hz,1H),7.05(ddd,J=6.3,3.4,1.6Hz,2H),4.94(d,J=5.0Hz,1H),4.71(t,J=5.8Hz,1H),4.3 8(t,J=12.1Hz,1H),3.90(dd,J=13.1,3.4Hz,1H),3.77(ddt,J=20.4,13.2,6.8Hz,2H),3.36(q,J =5.4Hz,2H),2.81(d,J=13.4Hz,2H),2.61(p,J=10.5Hz,2H),2.06(s,6H),1.56(p,J=13.1Hz,4H).

[0297] Example 31: Preparation of compounds 1-55

[0298] The preparation method of compounds 1-55 is similar to that of Example 2, except that: iodoethane in step 3 is replaced with an equimolar amount of (R)-4-(bromomethyl)-2,2-dimethyl-1,3-dioxolane, and then deprotected by hydrogen chloride-ethyl acetate solution to obtain 90 mg of white solid compound, with a yield of 56.8%.

[0299] 1 H NMR (400MHz, CDCl3) δ7.46 (dd, J=5.8, 2.9Hz, 1H), 7.42–7.31 (m, 4H), 7.29 (d, J=6. 7Hz,1H),7.17–7.03(m,3H),4.51(dt,J=12.7,7.3Hz,1H),4.11–3.97(m,2H),3.66 –3.55(m,1H),2.79(d,J=13.2Hz,2H),2.67(td,J=12.8,3.1Hz,2H),2.42–2.17(m, 2H),2.14(s,6H),2.05–1.82(m,2H),1.73(d,J=8.9Hz,2H),1.60(t,J=13.4Hz,2H).

[0300] Example 32: Preparation of compounds 1-56

[0301] The preparation method of compounds 1-56 is similar to that of Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of 1-iodo-2-methoxyethane, yielding 96 mg of white solid compound with a yield of 78.4%.

[0302] 1 H NMR(400MHz,DMSO-d6)δ7.42–7.35(m,4H),7.32(d,J=7.3Hz,1H),7.28(s,1H ),7.24–7.19(m,1H),7.06(qd,J=6.6,3.9Hz,2H),4.37(s,1H),3.99(dt,J=5. 7,3.0Hz,2H),3.59(dt,J=5.6,2.9Hz,2H),3.23(d,J=1.9Hz,3H),2.81(d,J=1 3.4Hz,2H),2.68–2.55(m,2H),2.06(d,J=1.9Hz,6H),1.53(q,J=13.6Hz,4H).

[0303] Example 33: Preparation of compounds 1-57

[0304] The preparation of compounds 1-57 was similar to that in Example 2, except that iodoethane in step 3 was replaced with 3-iodooxetine, yielding 45 mg of a pale yellow solid with a yield of 54%.

[0305] 1 H NMR (400MHz, DMSO-d6) δ7.59–7.50(m,1H),7.41(t,J=4.5Hz,5H),7.30(q,J=4.1Hz,1H),7.15(td,J=7.9,6.8,4.0Hz,2H),5.55(d,J=6.7Hz, 1H),5.12(t,J=6.6Hz,2H),4.98(q,J=7.4,6.6Hz,2H),2.82(d,J=13.2Hz,2H),2.61(q,J=13.4Hz,2H),2.08(s,6H),1.56(q,J=13.9Hz,4H).

[0306] Example 34: Preparation of compounds 1-58

[0307] The preparation method of compounds 1-58 is similar to that of Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of 1-(2-bromoethyl)-1H-1,2,4-triazole, yielding 20 mg of white solid compound with a yield of 15.6%.

[0308] 1H NMR (400MHz, CDCl3) δ7.95(s,1H),7.84(s,1H),7.45–7.26(m,6H),7.00(dt,J=28.7,7.6Hz,2H),6.66(d,J=7.8Hz,1H),4.58(t,J=5.8H z,2H),4.49(m,1H),4.33(t,J=5.8Hz,2H),2.80(d,J=13.8Hz,2H),2.68(m,2H),2.14(s,6H),1.78–1.67(m,2H),1.60(t,J=13.1Hz,2H).

[0309] Example 35: Preparation of compounds 1-59

[0310] The synthetic routes for compounds 1-59 are as follows:

[0311] Step 1: Preparation of tert-butyl(2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethyl)carbamate

[0312] The preparation method of the compound was similar to that in Example 2, except that iodoethane in step 3 was replaced with an equimolar amount of tert-butyl(2-bromoethyl)carbamate, yielding 82 mg of a pale yellow powder compound in 28.9% yield. MS m / z calculated value: 478.29; experimental value: 479.29 [M+H] + .

[0313] Step 2: Preparation of 1-(2-aminoethyl)-3-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0314] 82 mg (0.17 mmol) of tert-butyl(2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethyl)carbamate was dissolved in acetonitrile (10 mL) with sodium iodide (102 mg, 0.68 mmol). The mixture was heated to 85 °C, and TMS-Cl (74 mg, 0.68 mmol) was added under N2 protection. The reaction was monitored by TLC until complete. The pH was adjusted to alkaline by adding sodium bicarbonate. The mixture was washed twice with saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The residue was concentrated under reduced pressure and purified by column chromatography to give 60 mg of white powder, with a yield of 92.3%. MS m / z calculated value: 378.24; experimental value: 379.24 [M+H] + .

[0315] Step 3: Preparation of N-(2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethyl)methanesulfonamide

[0316] A mixture of 1-(2-aminoethyl)-3-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (60 mg, 0.16 mmol) and triethylamine (80 mg, 0.79 mmol) was added to 10 mL of DCM, followed by the addition of methanesulfonic anhydride (82 mg, 0.47 mmol). The reaction was carried out at room temperature for 2 h. The reaction was monitored by TLC until complete. 100 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 15 mg of compound 1-59 as a white solid, with a yield of 20.5%.

[0317] 1 H NMR(400MHz,DMSO-d6)δ7.38(d,J=4.5Hz,4H),7.36–7.32(m,1H),7.27(q, J=6.3,5.4Hz,2H),7.23–7.19(m,1H),7.11–7.06(m,2H),4.38(dt,J=12.5, 7.3Hz,1H),3.93(t,J=6.4Hz,2H),3.25(q,J=6.3Hz,2H),2.85(s,3H),2.81 (d, J=13.4Hz, 2H), 2.59 (q, J=12.3Hz, 2H), 2.06 (s, 6H), 1.62–1.48 (m, 4H).

[0318] Example 36: Preparation of compounds 1-60

[0319] The synthetic route for compounds 1-60 is as follows:

[0320] Step 1: Preparation of tert-butyl(2-((4-(dimethylamino)-4-phenylcyclohexyl)amino)-4-fluorophenyl)carbamate

[0321] A mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (143 mg, 1.38 mmol) and tert-butyl(2-amino-4-fluorophenyl)carbamate (300 mg, 1.33 mmol) was added to 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid, and stirred for 10 min. Then, sodium triacetoxyborohydride (843 mg, 3.98 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 86 mg of a yellowish-brown oily compound, with a yield of 15.3%. MS m / z calculated value: 427.26; experimental value: 428.27 [M+H] + .

[0322] Step 2: N 1 Preparation of 1,2-(4-(dimethylamino)-4-phenylcyclohexyl)-5-fluorobenzene-1,2-diamine

[0323] 86 mg (0.20 mmol) of tert-butyl(2-((4-(dimethylamino)-4-phenylcyclohexyl)amino)-4-fluorophenyl)carbamate was dissolved in 5 mL of ethyl acetate, followed by the addition of 2 mL of ethyl acetate hydrochloride solution (4 M). The reaction was allowed to proceed at room temperature for 3 h. The reaction was monitored by TLC until complete. 10 mL of saturated sodium bicarbonate solution was added to the system, and the mixture was extracted three times with DCM. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 54 mg of a yellowish-brown oily compound, with a yield of 81.8%. MS m / z calculated value: 327.21; experimental value: 328.22 [M+H] + .

[0324] Step 3: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-5-fluoro-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0325] To N 1 CDI (31 mg, 0.50 mmol) was added in a single dose to a solution of 54 mg (54 mg, 0.17 mmol) of 4-(dimethylamino)-4-phenylcyclohexyl)-5-fluorobenzene-1,2-diamine in acetonitrile (5 mL), and the mixture was reacted overnight at room temperature. The reaction was monitored by TLC until complete. A saturated sodium bicarbonate solution (10 mL) was added to the mixture, and the mixture was filtered. The filter cake was washed three times with acetonitrile (10 mL) and dried to give 54 mg of a white solid, with a yield of 93.1%. MS m / z calculated value: 353.19; experimental value: 354.20 [M+H] + .

[0326] Step 4: Preparation of 2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-6-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-N-methylacetamide

[0327] A mixture of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-5-fluoro-1,3-dihydro-2H-benzo[d]imidazol-2-one (54 mg, 0.15 mmol) and cesium carbonate (199 mg, 0.61 mmol) was added to 5 mL of DMF, followed by the addition of 2-bromo-N-methylacetamide (46 mg, 0.31 mmol). The reaction was carried out at room temperature for 12 h. The reaction was monitored by TLC until complete. 20 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by thin-layer chromatography to give compound 1-60 as a white solid, 55 mg, in 84.6% yield.

[0328] 1 H NMR (400MHz, DMSO-d6) δ8.12(q,J=4.6Hz,1H),7.38(d,J=4.4Hz,4H),7.27(dd,J=8.8,4.6Hz,2H),7.07(dd,J=9.2,2.6Hz,1H),6.93(m,1H), 4.45(s,2H),4.35(tt,J=12.3,4.8Hz,1H),2.80(d,J=13.4Hz,2H),2.62(d,J=4.6Hz,3H),2.59–2.52(m,2H),2.05(s,6H),1.65–1.45(m,4H).

[0329] Example 37: Preparation of compounds 1-61

[0330] The synthetic route for compounds 1-61 is as follows:

[0331] Step 1: N 1 N 1 -dimethyl-N 4 Preparation of 1,4-(3-nitropyridin-4-yl)-1-phenylcyclohexane-1,4-diamine

[0332] To a solution of 4-chloro-3-nitropyridine (244 mg, 1.54 mmol) and cesium carbonate (1.25 g, 4.62 mmol) in acetonitrile (15 mL), N,N-dimethyl-1-phenylcyclohexane-1,4-diamine (280 mg, 1.28 mmol) was added, and the mixture was heated to 70 °C for 5 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 100 mg of a yellow oily compound, with a yield of 19.1%. MS m / z calculated value: 340.19; experimental value: 341.19 [M+H] + .

[0333] Step 2: N 4 Preparation of 3,4-(4-(dimethylamino)-4-phenylcyclohexyl)pyridine-3,4-diamine

[0334] Add N to a 100mL single-necked flask 1 N 1 -dimethyl-N 4 -(3-nitropyridin-4-yl)-1-phenylcyclohexane-1,4-diamine (100 mg, 0.29 mmol), methanol (10 mL), palladium / carbon catalyst (40 mg, 10% wt) were reacted at room temperature for 5 h under a hydrogen balloon atmosphere. The reaction was monitored by TLC until complete. The system was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain 98 mg of a yellow-green flaky solid crude product. MS m / z calculated value: 310.22; experimental value: 311.22 [M+H] + .

[0335] Step 3: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one

[0336] To N 4 CDI (61 mg, 0.38 mmol) was added in a single dose to a solution of 98 mg (98 mg, 0.32 mmol) of 4-(dimethylamino)-4-phenylcyclohexyl)pyridine-3,4-diamine in 10 mL of acetonitrile, and the mixture was reacted overnight at room temperature. The reaction was monitored by TLC until complete. A saturated sodium bicarbonate solution (20 mL) was added to the mixture, and the mixture was filtered. The filter cake was washed three times with ethyl acetate (20 mL) and three times with H₂O (20 mL). The filter cake was collected and dried to give 50 mg of a white solid compound, with a yield of 47.2%. MS m / z calculated value: 336.29; experimental value: 337.30 [M+H] + .

[0337] Step 4: Preparation of 2-(1-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-1,2-dihydro-3H-imidazo[4,5-c]pyridin-3-yl)-N-methylacetamide

[0338] 15 mL of DMF was added to a mixture of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (50 mg, 0.15 mmol) and cesium carbonate (97 mg, 0.30 mmol), followed by the addition of 2-iodo-N-methylacetamide (34 mg, 0.22 mmol). The reaction was carried out at 100 °C for 12 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 36 mg of compound 1-61 as a white solid, with a yield of 70.3%.

[0339] 1 H NMR (400MHz, DMSO-d6) δ8.31 (s, 1H), 8.26 (d, J = 5.3Hz, 1H), 8.17 (q, J = 4.6Hz, 1H) ,7.43–7.34(m,4H),7.32(d,J=5.4Hz,1H),7.27(ddd,J=8.6,5.0,3.3Hz,1H),4.5 1(s,2H),4.37(tt,J=12.1,4.8Hz,1H),2.85–2.77(m,2H),2.63(d,J=4.6Hz,3H), 2.60–2.52(m,2H),2.06(s,6H),1.62(dd,J=12.1,5.1Hz,2H),1.57–1.45(m,2H).

[0340] Example 38: Preparation of compounds 1-62

[0341] The synthetic routes for compounds 1-62 are as follows:

[0342] Step 1: Preparation of ethyl 4-(4-(dimethylamino)-4-phenylcyclohexyl)-3-oxo-3,4-dihydroquinoxaline-2-carboxylate

[0343] Under a nitrogen atmosphere, diethyl 2-carbonylmalonate (93 mg, 0.53 mmol) was added dropwise to N2O2. 1The compound was reacted overnight at 80 °C with a toluene solution of 150 mg (0.48 mmol) of 4-(dimethylamino)-4-phenylcyclohexyl)phenyl-1,2-diamine. The reaction was monitored by TLC until complete. The solution was diluted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and purified by column chromatography to give 80 mg of a pale yellow solid, with a yield of 37.2%. MS m / z calculated value: 419.22; experimental value: 420.22 [M+H] + .

[0344] Step 2: Preparation of 4-(4-(dimethylamino)-4-phenylcyclohexyl)-3-oxo-3,4-dihydroquinoxaline-2-carboxylic acid

[0345] Ethyl 4-(4-(dimethylamino)-4-phenylcyclohexyl)-3-oxo-3,4-dihydroquinoxaloline-2-carboxylate (80 mg, 0.19 mmol) was slowly added to a solution of lithium hydroxide (4 mg, 0.38 mmol) in 12 mL of THF and reacted at room temperature for 2 h. The reaction was monitored by TLC until complete. The pH was adjusted to 1-2 with 1 M dilute hydrochloric acid, and the aqueous phase was extracted with ethyl acetate (10 mL x 3). The organic phases were combined and washed with saturated brine (15 mL x 2). The mixture was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by preparative thin-layer chromatography to obtain a pale yellow solid compound 1-62 60 mg, with a yield of 80.1%.

[0346] 1 H NMR (400MHz, DMSO-d6) δ12.09(s,1H),8.36(s,1H),7.76(d,J=7.9Hz,1H),7.60(t,J=7.9Hz,1H),7.41(d,J =6.8Hz,4H),7.40–7.26(m,2H),4.77(s,1H),2.85(d,J=13.6Hz,4H),2.12(d,J=10.5Hz,6H),1.60(s,4H).

[0347] Example 39: Preparation of compounds 1-63

[0348] The synthetic routes for compounds 1-63 are as follows:

[0349] Step 1: Preparation of ethyl 3-(dimethylamino)-2-(2-fluorobenzoyl)acrylate

[0350] 2-Fluorobenzoyl chloride (500 mg, 3.18 mmol), ethyl 3-(dimethylamino)acrylate (550 mg, 3.8 mmol), and toluene (20 mL) were added to a gai-shaped flask, followed by the slow addition of triethylamine (500 mg, 5 mmol). The system was then reacted at 90 °C for 12 h. The reaction was monitored by TLC until complete. After dilution with ethyl acetate and washing three times with saturated brine, the organic phase was separated, dried over anhydrous sodium sulfate, and concentrated by column chromatography to give 539 mg of a pale yellow solid, with a yield of 64%. MS m / z calculated value: 265.11; experimental value: 266.13 [M+H] + .

[0351] Step 2: Preparation of ethyl 3-((4-(dimethylamino)-4-phenylcyclohexyl)amino)-2-(2-fluorobenzoyl)acrylate

[0352] N,N-dimethyl-1-phenylcyclohexane-1,4-diamine (100 mg, 0.46 mmol) and ethyl 3-((4-(dimethylamino)-4-phenylcyclohexyl)amino)-2-(2-fluorobenzoyl)acrylate (100 mg, 0.37 mmol) were dissolved in 10 mL of tetrahydrofuran. The mixture was heated under reflux overnight. The reaction was monitored by TLC until complete. The solution was concentrated under reduced pressure and column chromatography to give 160 mg of a colorless oily compound, with a yield of 98.7%. MS m / z calculated value: 438.23; experimental value: 439.24 [M+H] + .

[0353] Step 3: Preparation of ethyl 1-(4-(dimethylamino)-4-phenylcyclohexyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate

[0354] A mixture of ethyl 3-((4-(dimethylamino)-4-phenylcyclohexyl)amino)-2-(2-fluorobenzoyl)acrylate (160 mg, 0.36 mmol), potassium carbonate (100 mg, 1.1 mmol), and N,N-dimethylformamide (10 mL) was heated under reflux overnight. The reaction was monitored by TLC until complete. The mixture was diluted with ethyl acetate and washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated by column chromatography to give 80 mg of a colorless oil, with a yield of 53.1%. MS m / z calculated value: 418.22; experimental value: 419.24 [M+H] + .

[0355] Step 4: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

[0356] A mixture of ethyl 1-(4-(dimethylamino)-4-phenylcyclohexyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (80 mg, 0.19 mmol) and methanol (10 mL) was added to 5 mL of 2N sodium hydroxide solution and refluxed. The reaction was monitored by TLC until complete. After acidification with hydrochloric acid, the aqueous phase was extracted with ethyl acetate to separate the organic phase. The solution was dried over anhydrous sodium sulfate and concentrated to give 65 mg of compound 1-63 as a colorless oil, with a yield of 87%.

[0357] 1 H NMR (400MHz, CDCl3) δ15.03(s,1H),12.54(s,1H),8.61–8.56(m,1H),8.50(s,1H),7.91(d,J=7.7Hz,2H),7.67(q,J=8.0,6.9Hz,3H) ,7.59(d,J=7.5Hz,2H),4.96(t,J=12.1Hz,1H),3.19–3.02(m,4H),2.63(d,J=4.7Hz,6H),2.42–2.31(m,2H),1.79(q,J=12.6Hz,2H).

[0358] Example 40: Preparation of compounds 1-64

[0359] The synthetic route for compounds 1-64 is as follows:

[0360] Step 1: Preparation of 4-(indoline-1-yl)-N,N-dimethyl-1-phenylcyclohexane-1-amine

[0361] Step 1 is similar to Step 3 of Example 3, except that the phenylenediamine in Example 3 is replaced with indoline, yielding 185 mg of a pale yellow solid compound in a yield of 65%. MS m / z calculated value: 320.22; experimental value: 321.23 [M+H] + .

[0362] Step 2: Preparation of 4-(indoline-1-yl)-N,N-dimethyl-1-phenylcyclohexane-1-amine hydrochloride

[0363] 4-(indolin-1-yl)-N,N-dimethyl-1-phenylcyclohexane-1-amine (185 mg, 0.57 mmol) was added to a 2 M hydrochloric acid solution in ethyl acetate (5 mL). After reacting at room temperature for 2 h, the reaction was complete as monitored by TLC. The crude product (180 mg) was obtained after concentration and used in the next reaction without purification, with a yield of 88.7%. MS m / z calculated value: 356.20; experimental value: 357.21 [M+H] + .

[0364] Step 3: Preparation of 4-(1H-indol-1-yl)-N,N-dimethyl-1-phenylcyclohexane-1-amine

[0365] Molecular sieve (2 g) and manganese dioxide (428 mg, 4.95 mmol) were added to a mixture of 4-(indoline-1-yl)-N,N-dimethyl-1-phenylcyclohexane-1-amine hydrochloride (180 mg, 0.51 mmol) and dichloromethane (15 ml). The reaction was carried out at room temperature for 36 h, and the reaction was monitored by TLC until it was complete. The solid was filtered with diatomaceous earth, the filter cake was washed with dichloromethane, concentrated, mixed and passed through a column to give compound 1-64 46 mg, with a yield of 28.3%.

[0366] 1 H NMR(400MHz, CDCl3) δ7.89(d,J=1.6Hz,1H),7.55–7.44(m,2H),7.41–7.28(m,7H),6.58(d,J=3.1Hz,1H),4.47– 4.19(m,1H),2.85(d,J=13.9Hz,2H),2.42(d,J=12.1Hz,2H),2.12(s,6H),2.03(d,J=12.6Hz,2H),1.61(s,2H).

[0367] Example 41: Preparation of compounds 1-68

[0368] The preparation method of compounds 1-68 is similar to that of Example 2, except that iodoethane in step 3 is replaced with an equimolar amount of 2-bromo-1-(pyrrolidine-1-yl)ethyl ketone, yielding 112 mg of white solid compound with a yield of 76.1%.

[0369] 1 H NMR (400MHz, DMSO-d6) δ7.42–7.36(m,4H),7.34(d,J=8.0Hz,1H),7.27(tt,J=5.5,2.8 Hz,1H),7.12–7.06(m,2H),7.06–6.96(m,1H),4.65(s,2H),4.37(dq,J=11.6,6.1Hz,1H ),3.58(t,J=6.8Hz,2H),3.29(d,J=6.8Hz,2H),2.81(d,J=13.4Hz,2H),2.61(q,J=12. 7Hz,2H),2.07(s,6H),1.94(q,J=6.8Hz,2H),1.80(p,J=6.9Hz,2H),1.62–1.47(m,4H).

[0370] Example 42: Preparation of compounds 1-69

[0371] The preparation method of compounds 1-69 is similar to that of Example 2, except that: o-diphenylamine in step 1 is replaced with an equimolar amount of 2,3-diaminofluorobenzene and iodoethane in step 3 is replaced with an equimolar amount of 2-bromo-N-methylacetamide, yielding 48 mg of white solid compound with a yield of 31.2%.

[0372] 1 H NMR (400MHz, DMSO-d6) δ8.10(d,J=4.8Hz,1H),7.41–7.34(m,4H),7.27(dq,J=8.2,3.8Hz,1H),7.21(d,J=7.9Hz,1H),7.08(td,J=8.2,5.1Hz,1H),6 .91(dd,J=11.4,8.4Hz,1H),4.49(s,2H),4.45–4.32(m,1H),2.81(d,J=13 .5Hz,2H),2.65–2.52(m,5H),2.05(s,6H),1.54(dq,J=29.8,14.5Hz,4H).

[0373] Example 43: Preparation of compounds 1-70

[0374] The preparation method of compounds 1-70 is similar to that of Example 2, except that iodoethane in step 3) is replaced with an equimolar amount of 2-bromo-N-methylpropionamide, yielding 65 mg of white solid compound with a yield of 34.6%.

[0375] 1 H NMR (400MHz, DMSO-d6) δ7.92(q,J=4.5Hz,1H),7.55–7.33(m,5H),6.99(d,J=7.8Hz,1H),6.89(t,J=7.7Hz,1H),6.74(t,J=7.7Hz,1H),6.32(d,J=7.9H z,1H),4.91(q,J=7.2Hz,1H),4.32(t,J=12.1Hz,1H),2.81(s,2H),2.53(d, J=4.5Hz,3H),2.12–1.91(m,8H),1.77–1.58(m,4H),1.42(d,J=7.3Hz,3H).

[0376] Example 44: Preparation of compounds 1-71

[0377] Step 1: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydrobenzo[c][1,2,5]thiadiazole 2,2-dioxide:

[0378] Diethylene glycol dimethyl ether (10 ml) was placed in a three-necked flask filled with nitrogen and heated to reflux. Then, N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine (270 mg, 0.87 mmol) and sulfonamide (150 mg, 1.56 mmol) were dissolved in diethylene glycol dimethyl ether (2 ml) and added dropwise to the reaction mixture. The mixture was stirred under reflux for 15 minutes. The precipitated solid was filtered, and the filter cake was washed with diethyl ether. The resulting solid did not require further purification and was used for the next reaction, yielding 140 mg of a pale yellow powder compound, with a yield of 43%. MS m / z calculated value: 371.17; experimental value: 372.17 [M+H] + .

[0379] Step 2: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-3-ethyl-1,3-dihydrobenzo[c][1,2,5]thiadiazole 2,2-dioxide:

[0380] The preparation method of the compound was similar to that in Example 2, except that 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one in step 3 was replaced with 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydrobenzo[c][1,2,5]thiadiazole 2,2-dioxide, yielding 85 mg of a pale yellow powder compound with a yield of 56%.

[0381] 1 H NMR (400MHz, CDCl3) δ7.52(t,J=7.6Hz,2H),7.44(d,J=6.7Hz,3H),6.88(t,J=7.8Hz,1H),6.76–6.65(m,2H),6.20(s,1H), 4.20–4.07(m,1H),3.73(q,J=7.2Hz,2H),2.89(d,J=9.7Hz,2H),2.29(s,6H),2.09(t,J=8.4Hz,6H),1.39(t,J=7.2Hz,3H).

[0382] Example 45: Preparation of compounds 1-72

[0383] The preparation method of compounds 1-72 is similar to that of Example 2, except that: the o-diphenylamine in step 1 is replaced with an equimolar amount of 4,5-difluorophenyl-1,2-diamine and the iodoethane in step 3 is replaced with an equimolar amount of 2-bromo-N-methylacetamide, yielding 42 mg of a grayish-white solid with a yield of 35.2%.

[0384] 1 H NMR (400MHz, DMSO-d6) δ8.08(q,J=4.6Hz,1H),7.50–7.38(m,4H),7.34(t,J=7.1Hz,1H),7.24(dd,J=10.7,7.1Hz,1H),6.42(dd,J =11.0,6.9Hz,1H),4.36–4.22(m,3H),2.76(d,J=12.9Hz,2H),2.56(d,J=4.5Hz,3H),1.98(s,6H),1.95(s,1H),1.75–1.58(m,5H).

[0385] Example 46: Preparation of compounds 1-73

[0386] The preparation method of the compound was similar to that in Example 7, except that 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one in step 1 was replaced with an equimolar amount of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-thione, yielding 60 mg of a pale yellow powder compound with a yield of 85%.

[0387] 1 H NMR (400MHz, DMSO-d6) δ11.45(s,1H),9.20(s,2H),7.88–7.81(m,2H),7.69(dd,J=8.5,4 .0Hz,3H),7.54(d,J=8.1Hz,1H),7.11(t,J=7.7Hz,1H),6.86(t,J=7.7Hz,1H),6.24(s,1 H),4.48(dd,J=11.7,5.7Hz,1H),3.74–3.58(m,3H),3.57(s,3H),3.52–3.44(m,1H),3.2 9(t,J=6.4Hz,2H),3.18–3.09(m,2H),2.55(s,6H),2.38(d,J=14.3Hz,2H),1.99(s,2H).

[0388] Example 47: Preparation of compounds 1-74

[0389] The preparation of compounds 1-74 was similar to that in Example 2, except that iodoethane in 3) was replaced with an equimolar amount of chloromethyl methyl sulfide, yielding 89 mg of a white solid with a yield of 62.5%.

[0390] 1 H NMR(400MHz, DMSO-d6)δ7.38(d,J=4.7Hz,5H),7.27(td,J=7.6,3.3Hz,2H),7.17–7.04(m,2H),5.04(s,2H),4.37 (dt,J=12.6,7.1Hz,1H),2.81(d,J=13.5Hz,2H),2.67–2.53(m,2H),2.09(s,3H),2.06(s,6H),1.62–1.47(m,4H).

[0391] Example 48: Preparation of compounds 1-75

[0392] The synthetic route for compounds 1-75 is as follows:

[0393] Step 1: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-3-(2-methoxyacetyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0394] 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (100 mg, 0.29 mmol), 1-chloro-3-methoxy-2-propanone (50 mg, 0.46 mmol), and dichloromethane (20 mL) were added to a gai-o flask, followed by the slow addition of triethylamine (124 mg, 1.23 mmol). The reaction was then allowed to proceed at room temperature for 24 h. The reaction was monitored by TLC until complete. The system was concentrated and passed through a column chromatography column to give 30 mg of compound 1-76 as a pale yellow solid, with a yield of 24%.

[0395] 1H NMR (400MHz, DMSO-d6) δ8.14(d,J=7.9Hz,1H),7.44(d,J=7.9Hz,1H),7.38(d ,J=4.4Hz,4H),7.31(d,J=7.8Hz,1H),7.28(s,1H),7.17(t,J=7.8Hz,1H),4.7 3(s,2H),4.42–4.33(m,1H),3.40(s,3H),2.82(d,J=13.6Hz,2H),2.60(q,J= 12.2Hz, 2H), 2.05 (s, 6H), 2.00 (q, J=7.1, 6.6Hz, 2H), 1.62 (d, J=12.1Hz, 2H).

[0396] Example 49: Preparation of compounds 1-76

[0397] The synthetic route for compounds 1-76 is as follows:

[0398] Step 1: Preparation of tert-butyl 3-((3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)azacyclobutane-1-carboxylic acid ester

[0399] Step 1 is similar to step 3 of Example 2, except that iodoethane is replaced with tert-butyl-3-(bromomethyl)azacyclobutane-1-carboxylic acid ester, yielding 150 mg of a pale yellow powder, with a yield of 49.8%. MS m / z calculated value: 504.31; experimental value: 505.32 [M+H] + .

[0400] Step 2: Preparation of compound 1-(azacyclobutane-3-ylmethyl)-3-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one.

[0401] 140 mg (0.3 mmol) of tert-butyl 3-((3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)azacyclobutane-1-carboxylic acid ester was dissolved in 10 mL of dichloromethane, followed by the addition of 5 mL of trifluoroacetic acid. The reaction was monitored by TLC until complete. The pH was adjusted to alkaline by adding sodium bicarbonate. The mixture was washed twice with saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The residue was concentrated under reduced pressure and purified by column chromatography to give 70 mg of compound 1-76 as a white powder, with a yield of 62.5%.

[0402] 1H NMR (400MHz, DMSO-d6) δ7.43–7.32(m,5H),7.30–7.22(m,2H),7.08(tt,J=7.5,6.0Hz,2H),4.38(dt,J=12.5,7.1Hz,1H),4.06(d,J=7.0Hz,2H),3. 63(t,J=8.2Hz,2H),3.49(t,J=7.5Hz,2H),3.09(q,J=7.4Hz,1H),2.80(d ,J=13.4Hz,2H),2.58(q,J=12.0Hz,2H),2.06(s,6H),1.62–1.46(m,4H).

[0403] Example 50: Preparation of compounds 1-77

[0404] The synthetic route for compounds 1-77 is as follows:

[0405] Step 1: Preparation of tert-butyl(2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethyl)carbamate

[0406] Step 1 is the same as step 1 in Example 34, yielding 80 mg of a pale yellow solid compound in 32% yield. MS m / z calculated value: 478.29; experimental value: 479.19 [M+H] + .

[0407] Step 2: Preparation of 1-(2-aminoethyl)-3-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0408] Step 2 is the same as step 2 in Example 34, yielding 60 mg of a white powder compound in 95% yield. MS m / z calculated value: 378.24; experimental value: 379.24 [M+H] + .

[0409] Step 3: Preparation of tert-butyl (N-(2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethyl)sulfonamide)carbamate

[0410] At 0°C, chlorosulfonyl isocyanate (95 mg, 0.67 mmol) was added dropwise to a DCM solution of tert-butanol (50 mg, 0.67 mmol) in a 50 ml round-bottom flask and stirred for 30 min. Triethylamine (341 mg, 3.37 mmol) was then added dropwise and stirred for 10 min. A DCM solution of 1-(2-aminoethyl)-3-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (140 mg, 0.33 mmol) was then added dropwise to the above system. The system was slowly heated to room temperature and reacted for 2 h. The reaction was monitored by TLC until complete. The reaction was quenched with brine. The mixture was extracted three times with 20 ml of DCM. The organic phases were combined and washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to obtain 120 mg of white powder, with a yield of 63.7%. MS m / z calculated value: 557.26; experimental value: 558.25 [M+H] + .

[0411] Step 4: Preparation of N-(2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethyl)sulfonamide

[0412] The compound tert-butyl(N-(2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethyl)sulfonamide)carbamate was dissolved in 10 ml of hydrochloric acid in a 1,4-dioxane solution. The reaction was monitored by TLC until complete. The pH was adjusted to alkaline by adding sodium bicarbonate. The mixture was washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate. The residue obtained by concentration under reduced pressure was purified by column chromatography to give 46 mg of compound 1-77 as a white powder, with a yield of 46%.

[0413] 1 H NMR (400MHz, DMSO-d6) δ7.44–7.36(m,4H),7.36–7.31(m,1H),7.28(dt,J=5.5,3.0H z,1H),7.26–7.22(m,1H),7.11–7.04(m,2H),6.79(t,J=6.1Hz,1H),6.65(s,2H),4. 42–4.33(m,1H),3.95(t,J=6.7Hz,2H),3.20–3.12(m,2H),2.81(d,J=13.3Hz,2H),2 .59(q,J=12.7Hz,2H),2.06(s,6H),1.58(d,J=15.0Hz,2H),1.50(d,J=12.6Hz,2H).

[0414] Example 51: Preparation of compounds 1-78

[0415] The preparation of compounds 1-78 was similar to that in Example 2, except that iodoethane in 3) was replaced with an equimolar amount of 2-chloromethyloxazole, yielding 112 mg of white solid with a yield of 74.7%.

[0416] 1 H NMR(400MHz, DMSO-d6)δ8.09(s,1H),7.42–7.33(m,5H),7.28(q,J=4.1Hz,1H),7.20–7.14(m,2H),7.11(td,J=7.6,1.4Hz,1H),7.05(t,J=7.6H z,1H),5.23(s,2H),4.39(tt,J=12.3,5.0Hz,1H),2.81(d,J=13.7Hz,2H),2.68–2.53(m,2H),2.06(s,6H),1.55(ddd,J=30.7,13.8,3.8Hz,4H).

[0417] Example 52: Preparation of compounds 1-79

[0418] The synthetic routes for compounds 1-79 are as follows:

[0419] Step 1: Preparation of 4-(dimethylamino)-4-phenylcyclohexane-1-carboxaldehyde

[0420] At 0°C, methoxymethyltriphenylphosphine chloride (1.26 g, 3.7 mmol) was added to a 100 mL Shrek tube, purged three times with N2, and 50 mL of anhydrous THF was added using a syringe. Then, n-butyllithium (1.4 mL, 2.5 mol / L in Hexane) was slowly added dropwise using a syringe, and the mixture was stirred for 30 min. Subsequently, 10 mL of a THF solution of 4-(dimethylamino)-4-phenylcyclohexane-1-one (500 mg, 2.3 mmol) was slowly added dropwise using a syringe. After the addition was complete, the mixture was allowed to react at room temperature overnight. The reaction was confirmed to be complete by TLC. The system was quenched with 2N HCl and stirred for another 2 hours. The mixture was then extracted with ethyl acetate (100 mL × 3 times), and the aqueous phase was collected. The pH of the aqueous phase was adjusted to 12 with concentrated NaOH solution, and the aqueous phase was extracted again with ethyl acetate (100 mL × 3 times). The organic phase was collected and evaporated to dryness to give 420 mg of a pale yellow oily 4-(dimethylamino)-4-phenylcyclohexane-1-carboxaldehyde, with a yield of 78.9%. MS m / z calculated value: 231.16; experimental value: 232.24 [M+H]+.

[0421] Step 2: N 1Preparation of 1,2-diamine (((4-(dimethylamino)-4-phenylcyclohexyl)methyl)phenyl-1,2-diamine)

[0422] To a mixture of 4-(dimethylamino)-4-phenylcyclohexyl-1-carboxaldehyde (300 mg, 1.30 mmol) and o-diphenylamine (168 mg, 1.30 mmol), 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid were added, and the mixture was stirred for 10 min. Then, sodium triacetoxyborohydride (550 mg, 2.60 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The combined organic phases were washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 210 mg of a pale yellow oily compound, with a yield of 50.0%. MS m / z calculated value: 323.24; experimental value: 324.35 [M+H]+.

[0423] Step 3: Preparation of 1-((4-(dimethylamino)-4-phenylcyclohexyl)methyl)-1,3-dihydro-2H-benzimidazol-2-one

[0424] To N 1 CDI (211 mg, 1.30 mmol) was added in a single dose to a solution of 4-(dimethylamino)-4-phenylcyclohexyl)methyl)phenyl-1,2-diamine (210 mg, 0.65 mmol) in acetonitrile (50 mL), and the mixture was reacted overnight at room temperature. The reaction was confirmed to be complete by TLC. 100 mL of ethyl acetate was added to the mixture, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 180 mg of compound 1-79 as a white gelatinous solid, with a yield of 79.2%.

[0425] 1 H NMR(400MHz, DMSO-d6)δ10.82(s,1H),7.33(d,J=7.5Hz,4H),7.27–7.18(m,1H),7.15–7.09(m,1H),7.02–6.94(m,3H),3.70 (d,J=7.2Hz,2H),2.60(d,J=13.6Hz,2H),2.02–1.81(m,7H),1.50(t,J=11.8Hz,2H),1.45–1.40(m,2H),1.34–1.27(m,2H).

[0426] Example 53: Preparation of compounds 1-80

[0427] The synthetic route for compounds 1-80 is as follows:

[0428] Step 1: Preparation of 1-((4-(dimethylamino)-4-phenylcyclohexyl)methyl)-3-ethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0429] 20 mL of DMF was added to a mixture of 1-((4-(dimethylamino)-4-phenylcyclohexyl)methyl)-1,3-dihydro-2H-benzimidazol-2-one (90 mg, 0.26 mmol) and cesium carbonate (250 mg, 0.75 mmol), followed by the addition of iodoethane (62 mg, 0.39 mmol). The reaction was carried out at 100 °C for 12 h. The reaction was monitored by TLC until complete. 100 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 82 mg of compound 1-80 as a white solid, with a yield of 83.5%.

[0430] 1 H NMR (400MHz, DMSO-d6) δ7.36–7.26(m,4H),7.26–7.16(m,3H),7.05(dd,J=5.8,3.2Hz,2H),3.88(q,J=7.1Hz,2H),3.74(d,J=7.3Hz,2H ),2.60(d,J=13.6Hz,2H),2.05–1.95(m,2H),1.93(s,6H),1.88–1.81(m,1H),1.56–1.45(m,2H),1.45–1.37(m,2H),1.26–1.21(m,3H).

[0431] Example 54: Preparation of compounds 1-81

[0432] The synthetic route for compounds 1-81 is as follows:

[0433] Step 1: Preparation of N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine)

[0434] To a mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (300 mg, 1.38 mmol) and o-diphenylamine (300 mg, 2.76 mmol), 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid were added, and the mixture was stirred for 10 min. Then, sodium triacetoxyborohydride (880 mg, 4.15 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 300 mg of a pale yellow oily compound, with a yield of 70.2%. MS m / z calculated value: 309.22; experimental value: 310.35 [M+H] + .

[0435] Step 2: Preparation of N-(2-((4-(dimethylamino)-4-phenylcyclohexyl)amino)phenyl)tetrahydro-2H-pyran-3-carboxamide

[0436] N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine (310 mg, 1.0 mmol), tetrahydro-2H-pyran-3-carboxylic acid (144 mg, 1.0 mmol), and DIPEA (258 mg, 2.0 mmol) were dissolved in 10 mL of DMF and stirred at room temperature for 5 min. Then, HATU (570 mg, 1.5 mmol) was added, and the reaction continued at room temperature for 2 h until complete. 100 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 290 mg of a white solid, with a yield of 68.7%. MS m / z calculated value: 421.27; experimental value: 422.33 [M+H] + .

[0437] Step 3: Preparation of N,N-dimethyl-1-phenyl-4-(2-(tetrahydro-2H-pyran-3-yl)-1H-benzo[d]imidazol-1-yl)cyclohexylamine

[0438] N-(2-((4-(dimethylamino)-4-phenylcyclohexyl)amino)phenyl)tetrahydro-2H-pyran-3-carboxamide (290 mg, 0.68 mmol) was dissolved in 10 mL of glacial acetic acid and reacted at 130 °C for 24 h. The reaction was confirmed to be complete by TLC. 100 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated sodium bicarbonate solution (200 mL × 3). The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 70 mg of compound 1-81 as a white solid, with a yield of 24.2%.

[0439] 1H NMR (400MHz, DMSO-d6) δ7.74(d,J=8.0Hz,1H),7.58(d,J=7.8Hz,1H),7.46–7.35(m,4H),7.32– 7.26(m,1H),7.20(t,J=7.4Hz,1H),7.14(t,J=7.5Hz,1H),4.67–4.55(m,1H),4.02(d,J=8.5Hz ,1H),3.92(d,J=11.2Hz,1H),3.64(t,J=10.8Hz,1H),3.45–3.37(m,2H),2.83(d,J=13.6Hz,2H ),2.68(d,J=9.0Hz,2H),2.11(s,6H),2.03–1.97(m,2H),1.77–1.60(m,4H),1.26–1.21(m,2H).

[0440] Example 55: Preparation of compounds 1-82

[0441] The synthetic route for compounds 1-82 is as follows:

[0442] Step 1: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,4-dihydroquinoxaline-2,3-dione

[0443] Step 1 was the same as step 1 in Example 16, yielding 54 mg of a white solid compound, with a yield of 24%. MS m / z calculated value: 363.19; experimental value: 364.22 [M+H] + .

[0444] Step 2: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-4-(2-methoxyethyl)-1,4-dihydroquinoxaline-2,3-dione

[0445] 1-Bromo-2-methoxyethane (36 mg, 0.26 mmol), cesium carbonate (193 mg, 0.56 mmol), and DMF (10 mL) were added to a gai flask. The system was then reacted at 60 °C for 4 h. The reaction was monitored by TLC until complete. 20 mL of ethyl acetate was added to the system, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative thin-layer chromatography to give 30 mg of compound 1-82 as a white solid, with a yield of 40.2%.

[0446] 1H NMR (400MHz, DMSO-d6) δ7.46(dd,J=10.1,4.0Hz,5H),7.36(d,J=6.1Hz,1H),7.18(t,J=7.8Hz,2H),6.98(s,1H),4.71(s,1H),4.26(t,J=5.9H z,2H),3.56(t,J=5.8Hz,2H),3.21(s,3H),2.78(d,J=13.1Hz,2H),2.33(q,J=13.1Hz,2H),1.99(s,6H),1.76(s,2H),1.62(d,J=12.5Hz,2H).

[0447] Example 56: Preparation of compounds 1-83

[0448] The synthetic route for compounds 1-83 is as follows:

[0449] Step 1: Preparation of ethyl 4-(4-(dimethylamino)-4-phenylcyclohexyl)-3-oxo-3,4-dihydroquinoxaline-2-carboxylate

[0450] Step 1 was the same as step 1 in Example 62, yielding 80 mg of a pale yellow solid compound in a yield of 69%. MS m / z calculated value: 419.22; experimental value: 420.12 [M+H] + .

[0451] Step 2: Preparation of 4-(4-(dimethylamino)-4-phenylcyclohexyl)-N-methyl-3-oxo-3,4-dihydroquinoxaline-2-carboxamide

[0452] A THF solution of ethyl 4-(4-(dimethylamino)-4-phenylcyclohexyl)-3-oxo-3,4-dihydroquinoxaloline-2-carboxylate (80 mg, 0.19 mmol) and an aqueous solution of methylamine (1 mL) were added to a sealed tube. The system was heated to 120 °C and reacted for 48 h. The reaction was monitored by TLC until complete. 20 mL of ethyl acetate was added to the system, and the mixture was washed twice with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative thin-layer chromatography to obtain 30 mg of a pale yellow solid of compound 1-83, with a yield of 38.8%.

[0453] 1H NMR (400MHz, DMSO-d6) δ8.70(q,J=4.7Hz,1H),8.38(s,1H),7.87(dd,J=7.9,1.6Hz,1H),7.70(ddd,J=8.7,7.2,1.7Hz,1H),7.48–7.34(m,5H ),7.29(td,J=6.3,1.9Hz,1H),5.66–5.05(m,1H),2.84(d,J=13.2Hz,3H),2.80(d,J=4.8Hz,4H),2.13–2.03(m,6H),1.59(d,J=12.4Hz,4H).

[0454] Example 57: Preparation of compounds 1-84

[0455] The synthetic route for compounds 1-84 is as follows:

[0456] Step 1: Preparation of N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine)

[0457] To a mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (300 mg, 1.38 mmol) and o-diphenylamine (300 mg, 2.76 mmol), 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid were added, and the mixture was stirred for 10 min. Then, sodium triacetoxyborohydride (880 mg, 4.15 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 300 mg of a pale yellow oily compound, with a yield of 70.2%. MS m / z calculated value: 309.22; experimental value: 310.35 [M+H] + .

[0458] Step 2: Preparation of 1-(4-(dimethylamino)-4-phenylcyclohexyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0459] CDI (190 mg, 1.16 mmol) was added in a single batch to a solution of N-(4-(dimethylamino-4-phenylcyclohexyl)phenyl-1,2-diamine (300 mg, 0.97 mmol) in acetonitrile (50 mL), and the mixture was reacted overnight at room temperature. The reaction was monitored by TLC until complete. A saturated sodium bicarbonate solution (100 mL) was added to the mixture, and the mixture was filtered. The filter cake was washed three times with ethyl acetate (50 mL) and three times with H₂O (50 mL). The filter cake was collected, dried, and purified by column chromatography to give 120 mg of compound 1-84 as a white solid, with a yield of 37%.

[0460] 1 H NMR (400MHz, DMSO-d6) δ10.84(s,1H),7.40–7.35(m,4H),7.28(d,J=7.1Hz,2H),7.05–6.96(m,3H),4.38 –4.27(m,1H),2.80(d,J=13.4Hz,2H),2.57(q,J=12.2,11.6Hz,2H),2.06(s,6H),1.52(q,J=13.2Hz,4H).

[0461] Example 58: Preparation of compounds 1-85

[0462] The synthetic route for compound 1-85 is as follows:

[0463] Step 1: Preparation of 2-((4-(dimethylamino)-4-phenylcyclohexyl)amino)phenol

[0464] To a mixture of 4-(dimethylamino)-4-phenylcyclohexane-1-one (300 mg, 1.38 mmol) and 2-aminophenol (300 mg, 2.76 mmol), 10 mL of 1,2-dichloroethane and 1 mL of glacial acetic acid were added, and the mixture was stirred for 10 min. Then, sodium triacetoxyborohydride (877 mg, 4.14 mmol) was added, and the mixture was reacted at room temperature for 4 h. The reaction was monitored by TLC until complete. Sodium hydroxide solution (5 mol / L, 50 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 100 mg of a pale yellow oily compound, with a yield of 23.3%. MS m / z calculated value: 310.20; experimental value: 311.20 [M+H] + .

[0465] Step 2: Preparation of 3-(4-(dimethylamino)-4-phenylcyclohexyl)benzo[d]oxazol-2(3H)-one

[0466] 10 mL of THF was added to a mixture of 2-((4-(dimethylamino)-4-phenylcyclohexyl)amino)phenol (100 mg, 0.32 mmol) and trichloromethyl carbonate (104 mg, 0.35 mmol), followed by the addition of triethylamine (65 mg, 0.64 mmol). The reaction was carried out at room temperature for 1 h. The reaction was monitored by TLC until complete. The residue obtained by concentration under reduced pressure was purified by column chromatography to give 1-85 46 mg of a pale yellow oily compound, with a yield of 42.3%.

[0467] 1H NMR (400MHz, DMSO-d6) δ7.51–7.40(m,4H),7.36(t,J=7.1Hz,1H),7.27(dd,J=7.9,1.2Hz,1H),7.04(td,J=7.8,1.3Hz,1H),6.96(td,J =7.7,1.2Hz,1H),6.42(d,J=7.7Hz,1H),4.28–4.17(m,1H),2.79(d,J=12.8Hz,2H),1.98(s,6H),1.93–1.82(m,2H),1.79–1.66(m,4H).

[0468] Example 59: Preparation of compounds 1-86

[0469] The preparation method of the compound is similar to that of 1-82, except that 1-bromo-2-methoxyethane in step 2 is replaced with an equimolar amount of chloromethyl methyl sulfide, yielding 40 mg of a pale yellow powder compound with a yield of 51%.

[0470] 1 H NMR (400MHz, CDCl3) δ7.66 (dd, J=7.9, 1.7Hz, 1H), 7.43–7.35 (m, 5H), 7.32–7.25 (m, 3H), 5.62 (s ,2H),2.92–2.76(m,4H),2.38(s,3H),2.17(d,J=3.1Hz,6H),1.69(tt,J=17.7,13.7,5.8Hz,5H).

[0471] Example 60: Preparation of compounds 1-87

[0472] The synthetic route for compound 1-87 is as follows:

[0473] The preparation of compound 1-87 was similar to steps 1, 2, and 3 of the preparation in Example 35, except that tert-butyl (2-amino-4-fluorophenyl) carbamate in step 1 was replaced with an equimolar amount of tert-butyl (2-aminobenzyl) carbamate, yielding 40 mg of white solid compound 1-87 with a yield of 67.3%.

[0474] 1H NMR (400MHz, DMSO-d6) δ7.48(d,J=8.4Hz,1H),7.37(d,J=5.1Hz,4H),7.27(s,1H),7.21(t,J=7.8Hz,1H),7.14(d,J=7.3Hz,1H),6.94(dd,J=14 .3,6.9Hz,2H),4.35(s,1H),4.13(d,J=2.1Hz,2H),2.70(dt,J=38.2,13.1Hz,4H),2.04(s,6H),1.56(d,J=12.1Hz,2H),1.48(d,J=12.3Hz,2H).

[0475] Example 61: Preparation of compounds 1-88

[0476] The preparation method of compounds 1-88 is similar to that of Example 53, except that iodoethane in step 1 is replaced with an equimolar amount of bromomethylcyclopropane, yielding 65 mg of white solid compound with a yield of 68.0%.

[0477] 1 H NMR (400MHz, DMSO-d6) δ7.39(t,J=7.5Hz,2H),7.32(d,J=7.7Hz,2H),7.26(t,J=7.3Hz,1H),7 .24–7.19(m,1H),7.15–7.08(m,1H),7.06–7.00(m,2H),3.70(d,J=6.9Hz,2H),3.53(d,J=7.3 Hz,2H),2.59(d,J=13.3Hz,2H),2.05–1.90(m,2H),1.91–1.79(m,7H),1.54(dd,J=13.5,3.8H z,2H),1.49–1.40(m,2H),0.80–0.74(m,1H),0.43(dt,J=8.0,2.9Hz,2H),0.36–0.29(m,2H).

[0478] Example 62: Preparation of compounds 1-89

[0479] The preparation method of the compound is similar to that of 1-82, except that 1-bromo-2-methoxyethane in step 2 is replaced with an equimolar amount of 2-bromoethylmethyl sulfide, yielding 70 mg of a pale yellow powder compound with a yield of 56%.

[0480] 1H NMR (400MHz, CDCl3) δ7.50(t,J=7.6Hz,2H),7.45–7.36(m,3H),7.18–7.09(m,2H),6.82(s,2H),5.05-4.92(m,1H),4.46–4. 26(m,2H),2.89–2.72(m,4H),2.50(q,J=13.2Hz,2H),2.23(s,3H),2.18(s,6H),1.94(d,J=13.4Hz,2H),1.82–1.70(m,2H).

[0481] Example 63: Preparation of compounds 1-90

[0482] The synthetic routes for compounds 1-90 are as follows:

[0483] Step 1: Preparation of methyl 3-amino-4-((4-(dimethylamino)-4-phenylcyclohexyl)amino)benzoate

[0484] 4-(dimethylamino)-4-phenylcyclohexane-1-one (500 mg, 2.3 mmol) and methyl 3,4-diaminobenzoate (458 mg, 2.76 mmol) were dissolved in 30 mL of dichloromethane and stirred at room temperature for 15 minutes. Then, sodium triacetoxyborohydride (975 mg, 4.6 mmol) solid was added, and the reaction was continued with stirring at room temperature for 4 hours. The reaction was monitored by TLC until complete. Sodium carbonate solution (1.6 mol / L, 60 mL) was added to the system, and the mixture was extracted five times with DCM. The organic phases were combined, washed three times with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 626 mg of a pale yellow oily compound, with a yield of 74.1%. MS m / z calculated value: 367.23; experimental value: 368.32 [M+H] + .

[0485] Step 2: Preparation of methyl 3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazolium-5-carboxylate

[0486] CDI (458 mg, 2.76 mmol) was added to a 100 mL Schleck tube, and the mixture was purged with nitrogen three times. Then, methyl 3-amino-4-((4-(dimethylamino)-4-phenylcyclohexyl)amino)benzoate and anhydrous tetrahydrofuran (30 mL) were added using a syringe, and the mixture was reacted at 45 °C for 3 h. The reaction was monitored by TLC until complete. After cooling to room temperature, 200 mL of ethyl acetate was added to the system, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 376 mg of a pink solid, with a yield of 56.25%. MS m / z calculated value: 393.21; experimental value: 394.29 [M+H] + .

[0487] Step 3: Preparation of methyl 3-(4-(dimethylamino)-4-phenylcyclohexyl)-1-(2-methoxyethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazolium-5-carboxylic acid

[0488] Methyl 3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazolium-5-carboxylate (376 mg, 0.96 mmol) and Cs₂CO₃ (939 mg, 2.88 mmol) were dissolved in 50 mL of N,N-dimethylformamide. Then, 1-bromo-2-methoxyethane (199 mg, 1.44 mmol) was added, and the mixture was reacted at 80 °C for 4 h. The reaction was monitored by TLC until complete. 150 mL of ethyl acetate was added to the system, and the mixture was washed five times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to give 299 mg of a white solid, with a yield of 71.29%. MS m / z calculated value: 436.22; experimental value: 437.25 [M+H] + .

[0489] Step 4: Preparation of 3-(4-(dimethylamino)-4-phenylcyclohexyl)-1-(2-methoxyethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-carboxylic acid

[0490] Methyl 3-(4-(dimethylamino)-4-phenylcyclohexyl)-1-(2-methoxyethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazolium-5-carboxylic acid (299 mg, 0.66 mmol) was dissolved in 30 mL of anhydrous methanol, followed by the addition of NaOH (106 mg, 2.64 mmol) and reaction at 130 °C for 4 h. The reaction was monitored by TLC until complete. The system was adjusted to acidity by adding HCl aqueous solution (2 mol / L, 10 mL), then extracted three times with ethyl acetate, washed twice with saturated brine, and the organic phase was separated. The residue was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to give compound 1-90 as a white solid, 241 mg, with a yield of 85.3%.

[0491] 1 H NMR (400MHz, DMSO-d6) δ10.78(s,1H),7.75(t,J=14.1Hz,2H),7.70–7.41(m,4H),7.27(dd,J=32.5,7.8Hz,2H),3.95–3.80(m,2H),3.51(dd,J=12 .5,7.3Hz,3H),3.41(d,J=19.9Hz,6H),3.05(t,J=11.7Hz,2H),2.38–2. 23(m,2H),2.10–1.90(m,4H),1.87–1.73(m,2H),1.65(d,J=15.2Hz,1H).

[0492] Example 64: Preparation of compounds 1-91

[0493] The synthetic route for compounds 1-91 is as follows:

[0494] Step 1: Preparation of 2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetic acid

[0495] 100 mg (0.24 mmol) of methyl 2-(3-(4-(dimethylamino)-4-phenylcyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetate was dissolved in methanol (10 mL). Sodium hydroxide (28.8 mg) was dissolved in water (5 mL) and added to the reaction mixture. The mixture was heated to reflux, and the reaction was monitored by TLC until complete. The pH was adjusted to acidic with dilute hydrochloric acid, and the mixture was washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate, and the residue was concentrated under reduced pressure and purified by column chromatography to obtain 65 mg of a pale yellow powder, with a yield of 66%. MS m / z calculated value: 393.21; experimental value: 394.21 [M+H] + .

[0496] 1 H NMR(400MHz, DMSO-d6)δ12.63(s,1H)7.60(dd,J=16.1,7.5Hz,4H),7.38–7.22(m,1H),7.08(d,J=7.8Hz,1H),6.95(t,J=7.7Hz,1H),6.79(t, J=7.7Hz,1H),6.31(d,J=7.9Hz,1H),4.48(s,2H),4.43-4.34(m,1H),2.91(dd,J=16.0,8.6Hz,2H),2.26(s,6H),2.01(p,J=6.6,5.8Hz,6H).

[0497] Biological component testing:

[0498] Test Example 1: Agonistaltic Activity Test

[0499] A) NOP cAMP detection experimental protocol

[0500] I. Reagents

[0501] II. Cells

[0502] III. Instruments and Equipment

[0503] IV. Experimental Methods

[0504] a) Preparation of compound masterbatch

[0505] (1) Detection reagent buffer: 1X stimulation buffer + 500μM IBMX.

[0506] (2) Positive control compounds were started at 1 μM and serially diluted 4-fold for a total of 10 spots (using ECHO operation).

[0507] (3) Forskolin was also started at 2.5 μM and serially diluted 4 times, for a total of 10 sites.

[0508] b) Compound transfer

[0509] (1) 50 nL of the compound was transferred to an OptiPlate-384 well plate using ECHO.

[0510] (2) Use ECHO to transfer 50 nL of Forskolin into the same well plate.

[0511] (3) Centrifuge at 1000 rpm for 5 seconds to homogenize the plate surface.

[0512] c) Preparation of cell suspensions

[0513] (1) Thaw one frozen NOP cell line rapidly in a 37°C water bath.

[0514] (2) Transfer the thawed cell suspension into a 15mL conical tube and add 10mL of HBSS.

[0515] (3) Centrifuge at 1000 rpm for 5 minutes at room temperature.

[0516] (4) Carefully aspirate the supernatant to avoid aspirating the cells.

[0517] (5) Gently tap the cell pellet to disperse it, and resuspend it with 10 mL of HBSS.

[0518] (6) Use a cell counter to count and detect viability.

[0519] (7) Resuspend the cells to 1×10⁻⁶ using detection buffer. 6 cell / mL concentration.

[0520] (8) Add 10 μL of cells to each well of the OptiPlate-384-well plate.

[0521] d) cAMP agonist activity assay:

[0522] (1) Incubate the plate with the sample at 37°C for 60 minutes.

[0523] (2) Add 10 μL of the detection reagent from the VKEY-BIO kit using an electric multichannel pipette.

[0524] (3) Seal the plate with TopSeal-A film and continue incubation at room temperature for 60 minutes.

[0525] (4) Read the signal on the EnVision microplate reader after removing the membrane.

[0526] B) FLIPR assay protocol for detecting MOR agonist activity

[0527] I. Experimental Materials

[0528] a) Cell lines:

[0529] MOR / HEK293 cells (MOR: μ-opioid receptor, stably expressed in HEK293 cells).

[0530] b) Culture medium:

[0531] DMEM medium, Invitrogen (catalog number: 11960);

[0532] Fetal bovine serum (FBS), Corning (Catalog No.: 35-076-CV);

[0533] G418 (Geneticin), Invitrogen (Catalog No.: 10131);

[0534] Penicillin-streptomycin mixture, Invitrogen (catalog number: 15140);

[0535] Blasticidin S HCl, Gibco (item number: A1139-03).

[0536] c) Reagents:

[0537] Fluo-4 Direct calcium fluorescent dye, Invitrogen (catalog number: F10471).

[0538] d) Instruments and equipment:

[0539] 384-well plate, Greiner (part number: 781090);

[0540] Cell counter: Vi-cell XR, Beckman Coulter;

[0541] Incubator: Thermo;

[0542] FLIPR TETRA system (for calcium flow detection).

[0543] II. Experimental Procedure

[0544] 1. Processing of compound plates:

[0545] The test compound was serially diluted 4-fold in 100% DMSO using an Echo system to obtain 10 concentration points. 750 nL of the compound was then transferred to the target 384-well plate.

[0546] Add 30 μL of detection buffer to each well.

[0547] 2. Treatment of cell plates:

[0548] Add 20 μL of Fluo-4 Direct to the cell plate (final volume 40 μL).

[0549] Incubate at 37°C and 5% CO2 for 50 minutes, then let stand at room temperature for 10 minutes.

[0550] 3. Compound addition and signal reading:

[0551] a) Operating steps:

[0552] 10 μL of the compound and reference drug were transferred from the compound plate to the cell plate;

[0553] Continue incubation at 37°C and 5% CO2 for 50 minutes, then at room temperature for 10 minutes;

[0554] Remove the cell plate from the incubator and place it into the FLIPR device, along with the compound plate and pipette tip; run the detection program on the FLIPRTETRA system;

[0555] b) Read the fluorescence signal and calculate the "Max-Min" signal starting from the first reading point. c) Perform data analysis using XLFIT software; the results are shown in Table 1.

[0556] Table 1. Agonistaltic activity of some compounds of the present invention on NOP and MOP.

[0557] Test Example 2: hERG Activity Assay

[0558] 1. Sample preparation

[0559] Preparation of blank control: Add an appropriate amount of DMSO to the extracellular fluid to obtain an extracellular fluid containing 0.3% DMSO, which can be used as the working solution for blank control.

[0560] Preparation of positive control: Weigh an appropriate amount of cisapride, dissolve it in an appropriate amount of dimethyl sulfoxide (DMSO), and then dilute it with extracellular fluid to prepare working solutions with concentrations of 1000 nM, 100 nM, 10 nM, 1 nM and 0.1 nM (ensure that the DMSO concentration is 0.3%).

[0561] Test substance preparation: Weigh an appropriate amount of the test substance, dissolve it in an appropriate amount of DMSO, and then prepare working solutions of the test substance with concentrations of 30 μM, 10 μM, 3 μM, 1 μM and 0.3 μM using extracellular fluid, ensuring that the concentration of DMSO in each working solution is 0.3%.

[0562] 2. Cell Culture

[0563] HEK-293 cells, stably expressing hERG potassium channels, were used. These cells were purchased from Creacell (catalog number: A-0320). Cells were cultured and passaged in DMEM medium containing 10% fetal bovine serum and 0.8 mg / mL G418 at 37°C with a carbon dioxide concentration of 5%. To maintain electrophysiological activity, the cell density must not exceed 80%.

[0564] Before patch-clamp detection, cells were treated with TrypLE. TMExpress separation, 4×10 3 The cells were seeded onto a coverslip and cultured in a 24-well plate (final volume: 500 μL). After 18 hours, the cells were tested.

[0565] 3. Electrophysiological recording

[0566] Extracellular fluid: K-007-1, 140mM NaCl, 3.5mM KCl, 1mM MgCl2·6H2O, 2mM CaCl2·2H2O, 10mM D-Glucose, 10mM HEPES, 1.25mM NaH2PO4·2H2O, pH adjusted to 7.4 with NaOH.

[0567] Intracellular fluid: K-002-2, 20mM KCl, 115mM K-Aspartic, 1mM MgCl2·6H2O, 5mM EGTA, 10mM HEPES, 2mM Na2-ATP, pH adjusted to 7.2 with KOH.

[0568] Patch-clamp assay: The voltage stimulation protocol for whole-cell patch-clamp recording of hERG currents is as follows: After whole-cell sealing, the cell membrane voltage is clamped at -80 mV. The clamp voltage is depolarized from -80 mV to -50 mV and maintained for 0.5 s (as a leakage current detection), then stepped to 30 mV and maintained for 2.5 s, and then rapidly restored to -50 mV and maintained for 4 s to excite the tail current of the hERG channel. Data is collected every 10 s to observe the effect of the drug on the hERG tail current. A 0.5 s stimulation at -50 mV is used as a leakage current detection. Experimental data are acquired using an IPA amplifier (Sutter Instrument) and stored in SutterPatch (with Igor Pro) software.

[0569] The patch-clamp procedure begins by using a microelectrode puller to draw a glass capillary into a recording electrode. The electrode, filled with intracellular fluid, is then placed into a microelectrode holder. Under an inverted microscope, the microelectrode manipulator is used to immerse the electrode in the extracellular fluid, and the electrode resistance (Rpip) is recorded. Next, the electrode is slowly brought into contact with the cell surface, and negative pressure is applied to aspirate and create a high-resistance seal (GΩ). Fast capacitance compensation is then performed, and continued negative pressure is applied to rupture the cell membrane, establishing a whole-cell recording mode. Finally, slow capacitance compensation is performed, and experimental parameters such as series resistance (Rs) are recorded. No leakage compensation is applied.

[0570] Once the hERG current recorded in whole cells stabilized, drug administration began. Each drug concentration was administered for 5 minutes (or until the current stabilized) before moving to the next concentration. Multiple concentrations were measured for each test compound. A coverslip containing cells was placed in a recording bath under an inverted microscope. Blank control solution and working solution of the test compound were perfused sequentially from low to high concentration through the recording bath using gravity perfusion, with fluid exchange performed using a peristaltic pump during recording. The current detected in the compound-free solution for each cell served as its control group. Each concentration was measured independently in triplicate using at least three cells. All electrophysiological experiments were performed at room temperature.

[0571] 4. Data Analysis

[0572] First, the peak tail current after each drug concentration was applied was recorded. compound Peak tail current (and blank control) control Normalize, and then calculate the inhibition rate corresponding to each drug concentration. The average inhibition rate was calculated for each concentration.

[0573] The dose-response curve was fitted using the Hill equation: Y = Bottom + (Top - Bottom) / (1 + 10^(LogIC)) 50 -X)*HillSlope)), where Bottom and Top represent the minimum and maximum inhibition values, respectively, X represents the logarithm of the compound concentration, and Y represents the peak tail current. compound / Peak tail current Control Value, IC 50 The values ​​represent the drug concentration at which the half-maximal inhibitory effect is achieved, and HillSlope represents the Hill coefficient. See Table 2 for the results.

[0574] Table 2. Activity of some compounds of the present invention on Herg.

[0575] Test Example 3: Liver microsomal metabolic stability test:

[0576] 1. Sample preparation

[0577] Working solutions of the test compound and positive control compound: The test compound and the positive control compound (dextromethorphan) were dissolved separately in DMSO to prepare 1 mM intermediate working solutions. The intermediate working solutions were then diluted with acetonitrile (ACN) to prepare 200 μM working solutions.

[0578] Phosphate buffer: Dissolve 8.709 g of dipotassium hydrogen phosphate (K₂HPO₄) in 950 mL of water, adjust the pH of the solution to 7.4 with hydrochloric acid, and then add water to a final volume of 1000 mL. Filter through a 0.22 μm filter membrane and store at 4°C for later use.

[0579] Incubation substrate working solution: Various liver microsomes (protein concentration 20 mg / mL) were melted in a 37°C water bath and then diluted with phosphate buffer solution to obtain liver microsome working solution with a protein concentration of 0.629 mg / mL.

[0580] NADPH working solution: Prepare a 5mM NADPH solution using the above phosphate buffer solution for later use.

[0581] Reaction termination solution: Prepare a stock solution of 1 mg / mL terfenadine / tolbutamide with DMSO, and then dilute it with a 50% methanol / 50% acetonitrile mixture to prepare a reaction termination solution containing 5 / 10 ng / mL (terfenadine / tolbutamide) internal standard.

[0582] 2. Incubation and Detection

[0583] 238.5 μL of different species of liver microsomal working solution was added to a 1.1 mL microvolume tube. Then, 1.5 μL of the working solution of the analyte or the positive control compound (dextromethorphan) working solution (200 μM) was added, and the mixture was incubated in a 37°C water bath for 5 min. 60 μL of NADPH solution was added to initiate the reaction. After thorough mixing, 30 μL of the reaction solution was transferred to 300 μL of the reaction termination solution at time points 0, 5, 15, 30, and 60 minutes. All samples were vortexed vigorously for 1 minute and then centrifuged at 4000 rpm for 15 minutes at 4°C. The supernatant was analyzed by LC-MS / MS.

[0584] 3. Data Analysis

[0585] The slope (ke) was determined by plotting the natural logarithm of the percentage of the remaining compound against time, and T was calculated using the first-order kinetic formula. 1 / 2 and intrinsic clearance rate (CL) int ):

[0586] The remaining percentage of the compound is calculated as follows: C t =C0*e -ke*t lnC t =lnC o –ke*t

[0587] According to the above formula, when At that time, it can be obtained

[0588] Intrinsic clearance rate CL int (μL / min / mg protein)=0.693*1000 / T 1 / 2 / Protein concentration (0.5 mg protein / mL) C t =C0×e -ke·t ,

[0589] Assume that the unbound portion (Fu) in the liver microsomal mixture is 100%.

[0590] The following physiological variables were used for predictive calculations:

[0591] The results of the liver microsomal stability test are shown in the table below.

[0592] Table 3. Stability of the compounds of the present invention to rat liver microsomes

[0593] Test Example 4: Solubility Test

[0594] Method for determining the solubility of the analyte in pH 7.4 phosphate buffer: Take an excess of the DMSO stock solution and place it in pH 7.4 phosphate buffer. Shake at 25℃-350rpm for 4 hours, then take a sample, filter it through a 0.22μm filter membrane, and take the filtrate to determine the concentration.

[0595] Table 4. Solubility of some compounds in this invention

[0596] The results show that the compounds of this invention exhibit good solubility.

[0597] Test Example 5: CYP450 Enzyme Inhibition Test

[0598] The effects of test substances on the activities of five isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A) of human liver microsomal cytochrome P450 (CYP) were evaluated using an in vitro assay system. Specific probe substrates for CYP450 isoenzymes were co-incubated with human liver microsomes and different concentrations of the test substance. Reduced nicotinamide adenine dinucleotide phosphate (NADPH) was added to initiate the reaction. After the reaction, the metabolites produced by the specific substrates were quantitatively detected by liquid chromatography-tandem mass spectrometry (LC-MS / MS) after sample processing, and the changes in CYP enzyme activity were measured. The IC50 values ​​were calculated. 50 The value is used to evaluate the inhibitory ability of the test substance against each CYP enzyme subtype.

[0599] The results showed that compounds 1-23, 1-54, 1-57, 1-60, 1-61, and 1-69 of the present invention had IC50 values ​​against CYP1A2, CYP2C19, and CYP3A, three of the five CYP isoenzymes. 50 All are greater than 30 μM; ICs of CYP2C9 and CYP2D6 50 All are greater than 10 μM.

[0600] Test Example 6: Pharmacokinetic Test in Rats:

[0601] This experiment evaluated the in vivo pharmacokinetics of rats via a single intravenous injection.

[0602] 1. Experimental methods and conditions: Male SD rats were used. All animals were fasted overnight and administered the test compound 0.16 mg / kg intravenously or 0.6 mg / kg orally. The prescription was 10% DMSO + 90% (30% HP-β-CD).

[0603] 2. Sampling information: Whole blood was collected at 0.083, 0.25, 0.5, 1.0, 2.0, 4.0, 7.0 and 24 h after drug administration. The blood was placed in a microcentrifuge tube containing EDTA-K2 anticoagulant and centrifuged at 4℃ and 4000rpm for 5 min. The supernatant was then collected and stored in a refrigerator at -75℃±15℃.

[0604] 3. Detection information: The drug concentration in plasma at different time points was detected by LC-MS / MS, and the relevant pharmacokinetic parameters were calculated using WinNonlin 8.3.1 software.

[0605] Table 5. Pharmacokinetic properties of some compounds in this invention.

[0606] Test Example 7: Spinal Nerve Ligation (SNL) Induced Mouse Model of Neuropathic Pain

[0607] Female SPF-grade C57BL / 6J mice were acclimatized for one week before the model was established. The specific establishment method is as follows:

[0608] 1. Spinal nerve ligation (SNL) model

[0609] (1) Disinfection of surgical instruments;

[0610] (2) After the experimental animals were anesthetized with isoflurane using a small animal gas anesthesia machine, they were placed in a prone position on the operating table. The hair and skin of the lumbar and hip bones were shaved and disinfected.

[0611] (3) After disinfection with iodine, make an opening of about 2 cm along the spine near the hip bone, separate the fascia and muscles, and expose the L5 transverse process.

[0612] (4) Carefully bite off the L5 transverse process with tweezers to expose the L5 nerve;

[0613] (5) The L5 nerve was separated with a glass needle and ligated with a 5-0 ligation suture.

[0614] (6) Suture the muscles and skin, and disinfect.

[0615] (7) Observe the overall recovery of the mice after surgery, as well as their gait, spontaneous pain, and weight-bearing preferences. Also, observe whether the skin on the back of the mice is healing well.

[0616] 2. Observation of general clinical symptoms

[0617] After modeling, observe the movement of the right hind limb of the mice. Mice with successful modeling showed abnormal gait, such as dragging or lameness of the right hind limb; spontaneous pain behavior, such as licking or stroking the affected limb; and weight-bearing preference, such as avoiding placing weight on the affected hind limb.

[0618] 3. Mechanical pain measurement

[0619] The mechanical withdrawal threshold in mice was determined using the classic up-down test. The 50% withdrawal threshold is defined as the mechanical force required to elicit a 50% withdrawal response from repeated mechanical stimulation. An acrylic box was placed on a metal screen. After the mice had acclimatized in the box for 30 minutes, Von Frey fibers were used to vertically stimulate the mid-sole of the mouse's hind paw for ≤4 seconds. A positive response was indicated by the mouse lifting or licking its paw; otherwise, a negative response was indicated.

[0620] Start by stimulating with a force of 0.4. If there is no withdrawal response, select the next higher force (0.6) to stimulate the hind toe. If there is a withdrawal response, select the next lower force (0.16), and so on. Continue this process, repeating the stimulation sequence 4 times for each subsequent response (from withdrawal to no withdrawal, or vice versa), for a total of 6 times. This completes the determination of the 50% withdrawal threshold. If the required force exceeds 2.0 or is lower than 0.02, the threshold for that side is directly recorded as 2.0 or 0.02. Each stimulation should be spaced 30 seconds apart. Maintain consistent measurement techniques throughout the experiment, including force direction, application speed, fiber bending, force stability, and force removal speed. Additionally, try to ensure consistent judgment criteria for the mice's responses. The 50% withdrawal threshold is calculated using the formula: 50% withdrawal threshold = 10log(X) + κδ (X is the intensity of the last stimulus; κ is the coefficient of different stimulus methods, which can be found in the coefficient table; δ is the average of the intervals between adjacent stimulus intensities, here δ = 0.224).

[0621] The 50% foot withdrawal threshold was measured and recorded at 0.5h, 1h, 3h, 6h and 8h after intravenous administration.

[0622] 4. Data Analysis

[0623] All experimental data were analyzed using GraphPad Prism 9 and IBM SPSS Statistics 19 software. Data are expressed as mean ± standard deviation (x ± s). Independent samples t-tests were used for comparisons between groups. p < 0.05, p < 0.01, and p < 0.001 were considered statistically significant.

[0624] 5. Experimental Results

[0625] In a mouse model of neuralgia induced by spinal nerve ligation (SNL), doses of 1-18, 1-23, 1-41, 1-51, 1-53, 1-56, 1-57, 1-60, and 1-68 at doses of 0.02–0.12 mg / kg all showed significant analgesic effects without any obvious side effects.

[0626] Test Example 8: MOP Combination Experiment

[0627] 1. Experimental Materials

[0628] 1) Cell Information

[0629] 2) Reagents

[0630] reagents

[0631] Consumables

[0632] 3) Instruments and equipment

[0633] Key instruments

[0634] 2. Test Sample

[0635] 3. Experimental Methods

[0636] 1) Membrane preparation and ligand preparation

[0637] 2) Compound dilution

[0638] Reference compound: 0.1 μM starting, 4-fold dilution, 8 concentration points.

[0639] Sample dilution: 0.5 μM starting, 4-fold dilution, 8 concentration points.

[0640] 3) Experimental Procedure

[0641] a. Using a multichannel pipette, transfer 1 μL of serially diluted reference and test compounds to the experimental plate. Based on the plate plot, transfer 1 μL of the nonspecific binding compound to the experimental plate to determine nonspecific binding (low plateau: LC). Based on the plate plot, transfer 1 μL of DMSO to the experimental plate to determine total binding (high plateau: HC).

[0642] b. According to the plate diagram, dispense 100 μL of the membrane stock solution into the plate.

[0643] c. Add 100 μL of radioactive ligand.

[0644] d. Sealing plate. The plate is vibrated at 300 rpm under specific conditions.

[0645] e. Soak each well of the Unifilter-96GF / C filter plate in 50 μL of 0.3% PEI for at least 0.5 hours at room temperature.

[0646] f. Once the binding experiment is complete, filter the reaction mixture through a GF / C plate using a Perkin Elmer Filtermate Harvester, and then wash each plate 6 times with cold wash buffer.

[0647] g. Dry the filter plate at 50 degrees Celsius for 1 hour.

[0648] h. After drying, seal the bottom of the filter plate pores with the Perkin Elmer Unifilter-96 bottom sealing tape. Add 50 μL of Perkin Elmer Microscint 20 mixture. Seal the top of the filter plate with the Perkin Elmer TopSeal-A sealing membrane.

[0649] i. Using Perkin Elmer MicroBeta 2 Reader counting filter membrane 3 H.

[0650] j. Calculate the inhibition rate using the following formula: % Inhibition rate = (1 - (experimental wells - average LC) / (average HC - average LC)) * 100%.

[0651] k. Analyze the data using Prism 5. Use the model "log(inhibitor) vs. response - Variable slope".

[0652] Fitting data.

[0653] 4. Experimental Results

[0654] The results are shown in Table 6.

[0655] Table 6. MOP binding activity of some compounds in this invention.

[0656] Test Example 9: Rat Foot Incision Pain Model

[0657] 1. Species, strain, weight, and sex of laboratory animals

[0658] SD rats, 200–260g, male.

[0659] 2. Instrument Information

[0660] 3. Compound preparation

[0661] a. Solvent preparation information

[0662] 2-hydroxypropyl-β-cyclodextrin was added to ultrapure water to prepare a 30% cyclodextrin solution.

[0663] b. Dosage

[0664] 0.04 mg / kg.

[0665] c. Test substance preparation information

[0666] Weigh the test substance into a container, add DMSO to dissolve it completely, and prepare a test substance stock solution with a concentration of 1 mg / mL. Take an appropriate amount of the stock solution according to the required dosage, dilute it with DMSO to 10% of the total volume, and then add 90% of the total volume of 30% cyclodextrin solution to dissolve and mix thoroughly to prepare a compound solution with a concentration of 0.008 mg / mL for the experiment. Prepare the solution immediately before use and avoid exposing the solution to air for more than 15 minutes.

[0667] 4. Test methods

[0668] a. Test Procedure

[0669] Animals were acclimatized for 7 days after purchase, with free access to food. On days 5-7 of acclimatization, rats were placed on a metal pain frame for 40-60 minutes to allow for acclimatization contact between the experimenters and the animals, in order to reduce the stress response of the animals to the experimenters. After acclimatization, the baseline values ​​of the animals were tested, and the animals were randomly grouped according to the baseline. The plantar incision pain model was established. On the first day after modeling, the drug was administered, and the mechanical pain threshold of all rats was measured before administration and at 0.5h, 1h, 3h, 6h, and 8h after administration.

[0670] b. Foot incision pain modeling

[0671] Disinfection of surgical instruments;

[0672] The animal was anesthetized and fixed in a prone position on the operating table.

[0673] The lateral hind limb is extended with the sole of the foot facing upwards, secured with surgical tape, and disinfected.

[0674] Make a 1cm longitudinal incision by cutting the skin fascia 0.5cm from the heel towards the toes with a blade.

[0675] Insert one end of the curved forceps below the outer edge of the flexor digitorum brevis and push the forceps into the inner side of the muscle to lift the flexor digitorum brevis.

[0676] Make a longitudinal incision in the muscle with a blade, making sure to cut the belly of the muscle in half;

[0677] The skin was sutured with 4-0 sutures and then disinfected.

[0678] c. Mechanical pain assessment

[0679] Pain assessment using the ascending method:

[0680] The experimental animals were placed on a mechanical metal mesh frame and left to stand for 30 minutes. The test was started after the animals stopped looking around and exploring and became relatively quiet.

[0681] After the test animal has settled, the sole of the hind limb to be tested is slowly and gently stimulated with Von-Frey fibers to bend the fibers, and the animal's withdrawal response is observed for 2-3 seconds. The test animal is stimulated sequentially with fibers of increasing weight, with each fiber weight being stimulated 5 times consecutively, with an interval of at least 10 seconds between each stimulation. If fewer than 3 positive responses occur, the above procedure is repeated with a larger fiber weight. When 3 or more positive responses occur on the first test, that fiber is considered the animal's pain threshold.

[0682] If an animal exhibits a paw-lifting, avoidance, or paw-licking response to a stimulus, it is marked as positive (×). Paw-withdrawal responses caused by physical activity are not included. If the animal does not exhibit any of the above behaviors, it is marked as negative (○).

[0683] Fiber weight (Rat): 0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0, 10.0, 15.0, cut value 15.0g.

[0684] d. Data Analysis

[0685] After the data were summarized and statistically analyzed, SPSS (version R26.0.0.0) data statistical software was used for analysis. Based on the SPSS analysis results, Graph Pad (version 8.0.2) software was used to draw graphs. The results are shown in Table 7.

[0686] Table 7: Mechanical pain thresholds of representative compounds before and 1, 3, 6, and 8 hours after administration.

[0687] Note: Mean±SD, n=6; *p<0.05:**-p<0.01,***-p<0.001,****-p<0.0001, vs.Model.

[0688] Compounds 1-18, 1-69, 1-23, and 1-60 of this invention have significant analgesic effects.

[0689] Test Example 10: Mouse Hot Plate Model

[0690] 1. Species, strain, weight, and sex of laboratory animals

[0691] Female SPF grade C57BL / 6J mice, weighing 16-20g.

[0692] 2. Instrument Information

[0693] 3. Compound preparation

[0694] a. Solvent preparation information

[0695] 2-hydroxypropyl-β-cyclodextrin was added to ultrapure water to prepare a 30% cyclodextrin solution.

[0696] b. Dosage

[0697] 0.08 mg / Kg.

[0698] c. Test substance preparation information

[0699] Weigh the test substance into a container, add DMSO to dissolve it completely, and prepare a test substance stock solution with a concentration of 1 mg / mL. Take an appropriate amount of the stock solution according to the required dosage, dilute it with DMSO to 10% of the total volume, and then add 90% of the total volume of 30% cyclodextrin solution to dissolve and mix thoroughly to prepare a compound solution with a concentration of 0.008 mg / mL for the experiment. Prepare the solution immediately before use and avoid exposing the solution to air for more than 15 minutes.

[0700] 4. Test methods

[0701] a. Test Procedure

[0702] Animals were placed in an acclimatization environment for 7 days after purchase, with free access to food. On days 5-7 of the acclimatization period, mice were placed in a transparent device of a hot plate apparatus for 30-40 minutes to allow experimental personnel to have acclimatization contact with the animals in order to reduce the stress response of the experimental animals to the experimental personnel.

[0703] After the adaptation period, the animals' baseline pain threshold was tested, and the animals were randomly grouped according to the baseline pain threshold.

[0704] The specific grouping and intervention details are shown in Table 8. The pain threshold was measured before administration and at 1 hour, 3 hours, 6 hours, and 8 hours after administration.

[0705] The maximum analgesic percentage (MPE) was calculated as [(post-dose pain threshold - pre-dose pain threshold) ÷ pre-dose pain threshold] × 100%, which served as an indicator for evaluating the analgesic effect of the compound.

[0706] b. Analgesia experiment

[0707] Turn on the power to the hot plate and set the temperature to 55±0.1℃.

[0708] Mice were placed in a hot plate and the timing was started simultaneously. The mice were carefully observed for behaviors such as licking their hind paws or jumping. Once such behaviors occurred, the timing was stopped immediately and the result was recorded as the baseline pain threshold (s). Animals with a baseline pain threshold that was too high (>25s) or too low (<10s) were removed. The baseline pain threshold of the mice was measured three times and then grouped evenly according to the average value.

[0709] Pain thresholds in mice were measured before administration and at 1, 3, 6, and 8 hours after administration. This was done to prevent injury to the mouse paws.

[0710] To prevent tissue burns, set the cutoff time to 60 seconds.

[0711] The maximum analgesic percentage (MPE) was calculated as [(post-dose pain threshold - pre-dose pain threshold) ÷ pre-dose pain threshold] × 100%, which served as an indicator for evaluating the analgesic effect of the compound.

[0712] 5. Data Analysis

[0713] All experimental data were analyzed using GraphPad Prism 9 and IBM SPSS Statistics 19 software. Data are expressed as mean ± standard deviation (x ± s). Independent samples t-tests were used for comparisons between groups. p < 0.05, p < 0.01, p < 0.001, and p < 0.0001 were considered statistically significant.

[0714] 6. Experimental Results

[0715] Table 8: Maximum analgesic percentage (%) of representative compounds before and 1, 3, 6, and 8 hours after administration.

[0716] Note:Mean±SD,n=5;*-p<0.05,**-p<0.01,***-p<0.001,****-p<0.0001,vs.Control;

[0717] One-fifth of the animals in the Cebranopadol group died within one hour after administration; the animals in the other groups showed no abnormalities.

[0718] The above embodiments, based on their numbers and corresponding structural formulas, are merely illustrative of the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein, without departing from the spirit and substance defined by the claims of the present invention; and such modifications or substitutions are still within the scope defined by the claims of the present invention.

Claims

1. Compound of Formula I: Its isomers, racemates, prodrugs, deuterated compounds, or pharmaceutically acceptable salts thereof, wherein: Ring B is a nitrogen-containing 5-7 membered heterocyclic alkyl group, containing... 5-6 membered heterocyclic alkyl groups, nitrogen-containing 5-6 membered heteroaryl groups; The ring C is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic alkyl; m, n, and p are integers from 1 to 4; each R1, each R2, each R3, R 1a3 , R 1d are each independently hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', -COOR5, -COR5, -NR5S(=0)2R6, -SR5, -OR5, =0, -S(=0)2R5, S(=0)2NR5R5', 6-10 membered aryl, 5-10 membered heteroaryl, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C 3-8 cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy are further substituted with one or more substituents independently selected from hydrogen, halogen, hydroxyl, cyano, -C 0-6 -NR5R5', -C 0- 6-CONR5R5', -C 0-6 -OR5, C 1-6 alkyl, haloC 1-6 alkyl, C 0-6 -SR5, C 1-6 alkoxy, haloC 1-6 alkoxy, -C 0-6 -COR5, -C 0-6 -C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 cycloalkoxy, 6-10 membered aryl, 5-10 membered heteroaryl, -COOR5, -COR5, -NR5S(=0)2R6, -S(=0)2R5, S(=0)2NR5R5'. R 1a1 , R 1a2 each independently is hydrogen, C 1-6 alkyl, C 1-6 alkoxy; alkyl, alkoxy can optionally be further substituted with one or more substituents independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy; R5, R5', R6are each independently selected from the group consisting of H, amino, C 1-6 alkyl, C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, -C 0-6 -OR7; wherein R7is C 1-6 alkyl; or R5, R5' together with the atoms to which they are attached form C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, said C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, said C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, =0, substituted by one or more substituents selected from the group consisting of halogen, hydroxy, amino, nitro, cyano, 2. The compound of claim 1, isomer, racemate, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof, wherein, Ring B is Alternatively, ring B is represents ring B Bit N and Connected.

3. The compound of claim 1 having the following formula IIa-IIk: ###0002### IIa IIb IIc IId IIe Hf Hg Hh Hi Hk or an isomer, racemate, prodrug, deuterated compound, or a pharmaceutically acceptable salt thereof. ###0003### IIj IIk X is selected from CR 2b R 2b ’, C=0; Y is selected from CR 2b R 2b ’, C=0; Z is selected from CR 2d R 2d ', O, S, NR 2d ; U is selected from N, CR 2b ; V is selected from N, CR 2c ; R 2b , R 2b , R 2c , R 2c , R 2d , R 2d , R 2e , R 2e , R 2f , R 2f each independently is hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', -COOR5, -COR5, -NR5S(=O)2R6, -SR5, -OR5, =O, -S(=O)2R5, S(=O)2NR5R5', 6-10 membered aryl, 5-10 membered heteroaryl, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C 3-8 cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy is further substituted with one or more substituents independently selected from hydrogen, halogen, hydroxyl, cyano, -C 0- 6-NR5R5', -C 0-6 -CONR5R5', -C 0-6 -OR5, C 1-6 alkyl, haloC 1-6 alkyl, C 0-6 -SR5, C 1-6 alkoxy, haloC 1-6 alkoxy, -C 0-6 -COR5, -C 0-6 -C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 cycloalkoxy, 6-10 membered aryl, 5-10 membered heteroaryl, -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5'. t is selected from 0, 1, or 2; s is selected from 0 or 1.

4. The compound of formula I, isomer, racemate, prodrug, deuterated compound or a pharmaceutically acceptable salt thereof according to claim 3 having the following formula IIIal-IIIa2, IIIbl, IIIcl-IIIc3, IIIdl, IIIel, IIIf 1, IIIgl, IIIhl, IIIil, IIIjl, IIIkl of the following structures: Preferably, R 1a3 selected from each R4is selected from hydrogen, halogen, hydroxyl, -C 0-6 -NR5R5', -C 0-6 -CONR5R5', -C 0-6 -OR5, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy; q is an integer between 1 and 5; R 3c , R 3d , R 3e , R 3f each independently is hydrogen, deuterium, halogen, hydroxyl, -NR5R5', -CONR5R5', -COOR5, -COR5, -NR5S(=0)2R6, -S(=0)2R5, S(=0)2NR5R5', 6-10 membered aryl, 5-10 membered heteroaryl, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, C 3-8 cycloalkoxy, 3-10 membered heterocycloalkoxy; aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkoxy, heterocycloalkoxy is further substituted with one or more substituents independently selected from hydrogen, halogen, hydroxyl, cyano, -C 0-6 -NR5R5', -C 0-6 -CONR5R5', -C 0-6 -OR5, C 1-6 alkyl, haloC 1- 6alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, -C 0-6 -COR5, -C 0-6 -C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 cycloalkoxy, 6-10 membered aryl, 5-10 membered heteroaryl, -COOR5, -COR5, -NR5S(=0)2R6, -S(=0)2R5, S(=0)2NR5R5'; R5, R5' are each independently selected from the group consisting of H, amino, C 1-6 alkyl, C 3-8 cycloalkyl, 3-10 membered heterocycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl.

5. The compound, isomer, racemate, prodrug, deuterated compound or pharmaceutically acceptable salt thereof of any one of claims 1-4, wherein, selected from Preferably, X and Y are each independently C=O and -CH2-; Preferably, Z is selected from O, -CH2-, -NH-, and -N(CH3)-; Preferably, R 1d selected from H, hydroxyl; Preferably, U and V are each independently N and CH; Preferably, the ring C is phenyl, pyridinyl, thiophene, pyrazinyl, pyrimidinyl, pyridazinyl, pyrroleyl, pyrazolyl, imidazoleyl, or thiazolyl. Preferably, R 1a3 Selected from C 1-6 Alkyl, phenyl, pyridyl, thiophene, wherein the alkyl, phenyl, pyridyl, or thiophene group is further composed of one or more radicals selected from hydrogen, halogen, hydroxyl, cyano, or -C. 0-6 -NR5R5'、-C 0-6 -CONR5R5'、-C 0-6 -OR5、C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -C 0-6 -COR5、-C 0-6 -C 3-8 Cycloalkyl, 3-10 membered heterocycloalkyl, -C 0-6 -C 3-8 Substitution of cycloalkoxy, 6-10 aryl, 5-10 heteroaryl, -COOR5, -COR5, -NR5S(=O)2R6, -S(=O)2R5, S(=O)2NR5R5' substituents.

6. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

7. A pharmaceutical composition comprising a compound, isomer, racemate, prodrug, deuterated compound or pharmaceutically acceptable salt thereof according to any one of claims 1-5, or a compound or pharmaceutically acceptable salt thereof according to claim 6, and a pharmaceutically acceptable excipient.

8. Use of the compound, isomer, racemate, prodrug, deuterated compound or pharmaceutically acceptable salt thereof according to any one of claims 1-5, or the compound or pharmaceutically acceptable salt thereof according to claim 6, or the pharmaceutical composition of claim 7 in the preparation of a medicament for treating and / or preventing diseases or disorders mediated by dual agonists of NOP and MOP.

9. Use of the compound, isomer, racemate, prodrug, deuterated compound or pharmaceutically acceptable salt thereof according to any one of claims 1-5, or the compound or pharmaceutically acceptable salt thereof according to claim 6, in the preparation of a medicament for treating and / or preventing neurological disorders; preferably, the neurological disorders include, but are not limited to, pain, neurodegenerative diseases, neuroinflammatory diseases, neuropsychiatric disorders, and drug abuse / dependence.

10. The compound, isomer, racemate, prodrug, deuterated compound, or pharmaceutically acceptable salt thereof according to any one of claims 1-5, or the compound of claim 6 or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition of claim 7 is used in the preparation of a treatment and / or prevention of anxiety states, stress and stress-related syndromes, depression, epilepsy, Alzheimer's disease, senile dementia, general cognitive impairment, learning and memory impairment (as a nootropic agent), withdrawal symptoms, alcohol and / or drug and / or drug abuse and / or dependence, sexual dysfunction, cardiovascular disease, etc. Use in medicines for the treatment of diseases such as hypotension, hypertension, tinnitus, pruritus, migraine, hearing loss, intestinal motility disorders, impaired food intake, anorexia, obesity, movement disorders, diarrhea, cachexia, urinary incontinence, or as a muscle relaxant, anticonvulsant, or anesthetic, or in combination with opioid analgesics or anesthetics, for diuresis or inhibition of natriuretic excretion, for anxiety, for regulating motor activity, for regulating neurotransmitter secretion and for treating associated neurodegenerative diseases, for treating withdrawal symptoms and / or for reducing opioid addiction tendencies.